Pier Mannuccio Mannucci

Pier Mannuccio Mannucci's AcademicInfluence.com Rankings

Computer Science

#1916

World Rank

#1990

Historical Rank

Machine Learning

#82

World Rank

#82

Historical Rank

Database

#136

World Rank

#139

Historical Rank

Artificial Intelligence

#159

World Rank

#163

Historical Rank

computer-science Degrees

Download Badge

Computer Science

Pier Mannuccio Mannucci's Degrees

PhD Computer Science University of Florence
Masters Artificial Intelligence Consorzio ICoN

Similar Degrees You Can Earn

Why Is Pier Mannuccio Mannucci Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Pier Mannuccio Mannucci's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study (2012) (2002)
Genome-wide meta-analyses identify multiple loci associated with smoking behavior (2010) (1107)
Genome-wide association of early-onset myocardial infarction with single nucleotide polymorphisms and copy number variants (2009) (1100)
Update on the pathophysiology and classification of von Willebrand disease: a report of the Subcommittee on von Willebrand Factor (2006) (1060)
The hemophilias--from royal genes to gene therapy. (2001) (969)
The coagulopathy of chronic liver disease. (2011) (925)
Large-scale association analysis identifies 13 new susceptibility loci for coronary artery disease (2011) (894)
Inherited Thrombophilia: Part 1 (1996) (637)
Persistent Activation of Coagulation Mechanism in Unstable Angina and Myocardial Infarction (1994) (611)
Expert position paper on air pollution and cardiovascular disease. (2015) (597)
1-DEAMINO-8-D-ARGININE VASOPRESSIN: A NEW PHARMACOLOGICAL APPROACH TO THE MANAGEMENT OF HAEMOPHILIA AND VON WILLEBRAND'S DISEASE (1977) (548)
The risk of recurrent deep venous thrombosis among heterozygous carriers of both factor V Leiden and the G20210A prothrombin mutation. (1999) (508)
Changes in health and disease of the metalloprotease that cleaves von Willebrand factor. (2001) (507)
An imbalance of pro- vs anti-coagulation factors in plasma from patients with cirrhosis. (2009) (499)
Impact, Diagnosis and Treatment of von Willebrand Disease (2000) (497)
Desmopressin (DDAVP) in the treatment of bleeding disorders: the first 20 years. (1997) (484)
Inherited thrombophilia: pathogenesis, clinical syndromes, and management. (1996) (474)
Recessively inherited coagulation disorders. (2004) (459)
Different risks of thrombosis in four coagulation defects associated with inherited thrombophilia: a study of 150 families. (1998) (412)
Heightened interaction between platelets and factor VIII/von Willebrand factor in a new subtype of von Willebrand's disease. (1980) (395)
Mechanism of Plasminogen Activator and Factor VIII Increase after Vasoactive Drugs (1975) (388)
Oligospecificity of the cellular adhesion receptor Mac-1 encompasses an inducible recognition specificity for fibrinogen (1988) (382)
Air pollution and cardiovascular disease. (2012) (377)
A Randomized Trial of Factor VIII and Neutralizing Antibodies in Hemophilia A. (2016) (374)
Cost of care and quality of life for patients with hemophilia complicated by inhibitors: the COCIS Study Group. (2003) (368)
Thrombin generation in patients with cirrhosis: The role of platelets (2006) (361)
Inherited Thrombophilia*: Part 2 (1996) (308)
Health Effects of Ambient Air Pollution in Developing Countries (2017) (302)
Desmopressin: a nontransfusional form of treatment for congenital and acquired bleeding disorders. (1988) (291)
The Thrombogram in Rare Inherited Coagulation Disorders: Its Relation to Clinical Bleeding (2002) (285)
Response of Factor VIII/von Willebrand Factor to DDAVP in Healthy Subjects and Patients with Haemophilia A and von Willebrand's Disease (1981) (284)
Prevention and treatment of major blood loss. (2007) (282)
ADAMTS13 autoantibodies in patients with thrombotic microangiopathies and other immunomediated diseases. (2005) (275)
Polypharmacy, length of hospital stay, and in-hospital mortality among elderly patients in internal medicine wards. The REPOSI study (2011) (273)
Role of the JAK2 mutation in the diagnosis of chronic myeloproliferative disorders in splanchnic vein thrombosis (2006) (269)
Tissue-factor antigen and activity in human coronary atherosclerotic plaques (1997) (256)
IMPROVEMENT IN THE HAEMOSTATIC DEFECT OF URAEMIA AFTER TREATMENT WITH RECOMBINANT HUMAN ERYTHROPOIETIN (1987) (255)
N-Terminal Pro-Brain Natriuretic Peptide on Admission Has Prognostic Value Across the Whole Spectrum of Acute Coronary Syndromes (2004) (249)
DEFICIENCIES OF PROTEIN C, AN INHIBITOR OF BLOOD COAGULATION (1982) (248)
Multimeric composition of factor VIII/von Willebrand factor following administration of DDAVP: implications for pathophysiology and therapy of von Willebrand's disease subtypes (1982) (247)
Hypercoagulability in centenarians: the paradox of successful aging. (1995) (243)
The Coagulopathy of Chronic Liver Disease (2012) (240)
ADAMTS13 and anti-ADAMTS13 antibodies as markers for recurrence of acquired thrombotic thrombocytopenic purpura during remission (2008) (240)
Clinical and molecular predictors of thrombocytopenia and risk of bleeding in patients with von Willebrand disease type 2B: a cohort study of 67 patients. (2009) (240)
Rare coagulation deficiencies (2002) (238)
Treatment of von Willebrand's disease (1997) (237)
Multiple diseases and polypharmacy in the elderly: challenges for the internist of the third millennium (2011) (232)
Transmission of Hepatitis A to Patients with Hemophilia by Factor VIII Concentrates Treated with Organic Solvent and Detergent To Inactivate Viruses (1994) (232)
Hyperhomocysteinemia in cerebral vein thrombosis. (2003) (229)
Risk Factors and Recurrence Rate of Primary Deep Vein Thrombosis of the Upper Extremities (2004) (228)
Large-Scale Gene-Centric Analysis Identifies Novel Variants for Coronary Artery Disease (2011) (228)
Effects of exposure to air pollution on blood coagulation (2007) (226)
No Evidence of Association Between Prothrombotic Gene Polymorphisms and the Development of Acute Myocardial Infarction at a Young Age (2003) (221)
Biologic response to desmopressin in patients with severe type 1 and type 2 von Willebrand disease: results of a multicenter European study. (2004) (218)
Risk factors for thrombophilia in extrahepatic portal vein obstruction (2005) (217)
Epitope mapping of ADAMTS13 autoantibodies in acquired thrombotic thrombocytopenic purpura. (2004) (216)
Exposure to particulate air pollution and risk of deep vein thrombosis. (2008) (211)
Von Willebrand's disease in the year 2003: towards the complete identification of gene defects for correct diagnosis and treatment. (2003) (210)
Past, present and future of hemophilia: a narrative review (2012) (206)
Environmental risk factors for inhibitor development in children with haemophilia A: a case–control study (2005) (203)
Conjugated estrogens for the management of bleeding associated with renal failure. (1986) (200)
Rare Coagulation Disorders (1999) (197)
Effects on health of air pollution: a narrative review (2015) (194)
A common mutation in the methylenetetrahydrofolate reductase gene (C677T) increases the risk for deep-vein thrombosis in patients with mutant factor V (factor V:Q506). (1997) (193)
von Willebrand factor cleaving protease (ADAMTS13) is deficient in recurrent and familial thrombotic thrombocytopenic purpura and hemolytic uremic syndrome. (2002) (192)
Severe hemophilia with mild bleeding phenotype: molecular characterization and global coagulation profile (2010) (192)
A shortened activated partial thromboplastin time is associated with the risk of venous thromboembolism. (2004) (189)
Identification of a new congenital defect of platelet function characterized by severe impairment of platelet responses to adenosine diphosphate. (1992) (187)
Clinical manifestations and complications of childbirth and replacement therapy in 385 Iranian patients with type 3 von Willebrand disease. (2000) (187)
Modern treatment of haemophilia. (1995) (186)
The incidence of venous thromboembolism in asymptomatic carriers of a deficiency of antithrombin, protein C, or protein S: a prospective cohort study. (1999) (183)
How I treat age-related morbidities in elderly persons with hemophilia. (2009) (183)
Prediction of Deep Vein Thrombosis after Elective Hip Replacement Surgery by Preoperative Clinical and Haemostatic Variables: The ECAT DVT Study (1999) (181)
Thrombogenicity and cardiovascular effects of ambient air pollution. (2011) (179)
Treatment of von Willebrand disease with a high-purity factor VIII/von Willebrand factor concentrate: a prospective, multicenter study. (2002) (179)
High thrombin generation measured in the presence of thrombomodulin is associated with an increased risk of recurrent venous thromboembolism (2008) (178)
Abnormalities of hemostasis in chronic liver disease: reappraisal of their clinical significance and need for clinical and laboratory research. (2007) (177)
Mild to moderate reduction of a von Willebrand factor cleaving protease (ADAMTS-13) in pregnant women with HELLP microangiopathic syndrome. (2003) (177)
Acquired dysfunction due to the circulation of "exhausted" platelets. (1980) (176)
A factor V genetic component differing from factor V R506Q contributes to the activated protein C resistance phenotype. (1997) (173)
Back to the future: a recent history of haemophilia treatment (2008) (171)
Patterns of development of tachyphylaxis in patients with haemophilia and von Willebrand disease after repeated doses of desmopressin (DDAVP) (1992) (169)
Treatment of acquired von Willebrand syndrome in patients with monoclonal gammopathy of uncertain significance: comparison of three different therapeutic approaches. (1998) (169)
Studies on the prolonged bleeding time in von Willebrand's disease. (1976) (168)
DDAVP enhances platelet adherence and platelet aggregate growth on human artery subendothelium. (1984) (167)
How I treat patients with von Willebrand disease. (2001) (166)
Risk of venous thromboembolism after air travel: interaction with thrombophilia and oral contraceptives. (2003) (165)
Drug therapy: Prevention and treatment of major blood loss (2007) (162)
Evidence that low protein C contributes to the procoagulant imbalance in cirrhosis. (2013) (161)
Clinical Manifestations and Management of Inherited Thrombophilia: Retrospective Analysis and Follow-up after Diagnosis of 238 Patients with Congenital Deficiency of Antithrombin III, Protein C, Protein S (1994) (161)
The coagulopathy of cirrhosis assessed by thromboelastometry and its correlation with conventional coagulation parameters. (2008) (159)
Resistance to Activated Protein C in Nine Thrombophilic Families: Interference in a Protein S Functional Assay (1993) (158)
Absence of hepatitis after treatment with a pasteurized factor VIII concentrate in patients with hemophilia and no previous transfusions. (1987) (157)
Treatment of von Willebrand's Disease. (2004) (157)
von Willebrand factor cleaving protease (ADAMTS‐13) and ADAMTS‐13 neutralizing autoantibodies in 100 patients with thrombotic thrombocytopenic purpura (2004) (153)
Guidelines for the diagnosis and management of von Willebrand disease in Italy (2002) (152)
Risk of venous thromboembolism and clinical manifestations in carriers of antithrombin, protein C, protein S deficiency, or activated protein C resistance: a multicenter collaborative family study. (1999) (150)
Quality of life is associated to the orthopaedic status in haemophilic patients with inhibitors (2006) (150)
Controlled trial of desmopressin in liver cirrhosis and other conditions associated with a prolonged bleeding time (1986) (149)
Hemostatic drugs. (1998) (149)
Studies of the pathophysiology of acquired von Willebrand's disease in seven patients with lymphoproliferative disorders or benign monoclonal gammopathies. (1984) (148)
Changing Concepts of Cirrhotic Coagulopathy (2017) (148)
Association of Anticholinergic Burden with Cognitive and Functional Status in a Cohort of Hospitalized Elderly: Comparison of the Anticholinergic Cognitive Burden Scale and Anticholinergic Risk Scale (2013) (147)
Purinoceptors on blood platelets: further pharmacological and clinical evidence to suggest the presence of two ADP receptors (1995) (143)
The low risk of hepatitis C virus transmission among sexual partners of hepatitis C-infected hemophilic males: an international, multicenter study. (1992) (143)
Thrombotic risk factors: Basic pathophysiology (2010) (143)
Binding of von Willebrand factor to glycoproteins Ib and IIb/IIIa complex: affinity is related to multimeric size (1989) (143)
Immunoradiometric Assay of Factor VIII Related Antigen, with Observations in 32 Patients with von Willebrand's Disease (1976) (142)
The risk of venous thromboembolism in family members with mutations in the genes of factor V or prothrombin or both. (2000) (140)
Risk of Pregnancy-related Venous Thrombosis in Carriers of Severe Inherited Thrombophilia (2001) (140)
High prevalence of antibody to hepatitis C virus in multitransfused hemophiliacs with normal transaminase levels. (1990) (140)
Detection of the imbalance of procoagulant versus anticoagulant factors in cirrhosis by a simple laboratory method (2010) (140)
Venous Thromboembolism in Von Willebrand Disease (2002) (138)
Living Near Major Traffic Roads and Risk of Deep Vein Thrombosis (2009) (136)
ADAMTS13 activity to antigen ratio in physiological and pathological conditions associated with an increased risk of thrombosis (2007) (136)
Hypercoagulability in patients with type 2 diabetes mellitus detected by a thrombin generation assay (2011) (135)
Laboratory investigation of thrombophilia. (2001) (132)
Human parvovirus B19 infection in hemophiliacs first infused with two high‐purity, virally attenuated factor Vlll concentrates (1992) (132)
Health status and quality of life of elderly persons with severe hemophilia born before the advent of modern replacement therapy (2009) (132)
Comparison of four virus-inactivated plasma concentrates for treatment of severe von Willebrand disease: a cross-over randomized trial. (1992) (129)
Hemostasis Testing during Massive Blood Replacement A Study of 172 Cases (1982) (129)
Genetic diagnosis of haemophilia and other inherited bleeding disorders (2006) (129)
Incidence of thrombotic complications in patients with haematological malignancies with central venous catheters: a prospective multicentre study (2005) (128)
Hemophilia: treatment options in the twenty‐first century (2003) (128)
Low Platelet 2β1 Levels in Type I von Willebrand Disease Correlate With Impaired Platelet Function in a High Shear Stress System (1999) (127)
Short‐term effects of air pollution on cardiovascular diseases: outcomes and mechanisms (2007) (127)
Report of the Working Party on Acquired Inhibitors of Coagulation: Studies of the “Lupus” Anticoagulant (1983) (126)
Binding of fibrinogen to human monocytes. (1986) (123)
Different bleeding risk in type 2A and 2M von Willebrand disease: a 2‐year prospective study in 107 patients (2012) (123)
Incidence of bleeding symptoms in 100 patients with inherited afibrinogenemia or hypofibrinogenemia (2006) (122)
Effects of secondary prophylaxis started in adolescent and adult haemophiliacs (2008) (122)
Missense mutations in the human beta fibrinogen gene cause congenital afibrinogenemia by impairing fibrinogen secretion. (2000) (122)
Hemophilia A in the third millennium. (2013) (121)
Association between clusters of diseases and polypharmacy in hospitalized elderly patients: results from the REPOSI study. (2011) (119)
Acquired coagulation disorders: revisited using global coagulation/anticoagulation testing (2009) (119)
Decrease in protein C antigen and formation of an abnormal protein soon after starting oral anticoagulant therapy (1984) (119)
Comparison of the rates of joint arthroplasty in patients with severe factor VIII and IX deficiency: an index of different clinical severity of the 2 coagulation disorders. (2009) (117)
Plasma levels of von Willebrand factor regulate ADAMTS‐13, its major cleaving protease (2004) (117)
Von Willebrand factor cleaving protease (ADAMTS-13) in 123 patients with connective tissue diseases (systemic lupus erythematosus and systemic sclerosis). (2003) (117)
A 6-month versus a 12-month surveillance for hepatocellular carcinoma in 559 hemophiliacs infected with the hepatitis C virus. (2003) (117)
CYP2C9 genotypes and dose requirements during the induction phase of oral anticoagulant therapy (2004) (117)
Thrombosis during Pregnancy and Surgery in Patients with Congenital Deficiency of Antithrombin III, Protein C, Protein S (1994) (116)
The bleeding score predicts clinical outcomes and replacement therapy in adults with von Willebrand disease. (2014) (116)
Molecular defects in type 3 von Willebrand disease: updated results from 40 multiethnic patients. (2003) (116)
The transfusion-associated transmission of parvovirus B19. (1999) (116)
Introduction. Rare bleeding disorders: general aspects of clinical features, diagnosis, and management. (2009) (115)
High Prevalence of Hyperhomocysteinemia in Patients with Inflammatory Bowel Disease: a Pathogenic Link with Thromboembolic Complications? (1998) (115)
Multimorbidity and polypharmacy in the elderly: lessons from REPOSI (2014) (115)
Inherited risk factors for venous thromboembolism (2014) (115)
Pharmacokinetics and safety of a novel recombinant human von Willebrand factor manufactured with a plasma-free method: a prospective clinical trial. (2013) (114)
Global hemostasis tests in patients with cirrhosis before and after prophylactic platelet transfusion (2013) (114)
ABO blood group and thrombotic vascular disease (2014) (112)
The varied sensitivity of partial thromboplastin and prothrombin time reagents in the demonstration of the lupus-like anticoagulant. (2009) (112)
Heparin in pregnant women with previous placenta-mediated pregnancy complications: a prospective, randomized, multicenter, controlled clinical trial. (2012) (112)
Are Capillary Whole Blood Coagulation Monitors Suitable for the Control of Oral Anticoagulant Treatment by the International Normalized Ratio? (1993) (111)
A Prospective Multicenter Study of Hepatocellular Carcinoma in Italian Hemophiliacs With Chronic Hepatitis C (1998) (111)
Time to face the challenge of multimorbidity. A European perspective from the joint action on chronic diseases and promoting healthy ageing across the life cycle (JA-CHRODIS). (2015) (110)
von Willebrand factor/factor VIII concentrate (Haemate® P) dosing based on pharmacokinetics: a prospective multicenter trial in elective surgery (2007) (109)
Treatment of von Willebrand Disease. (1998) (108)
Report of a joint WHO/WFH meeting on the control of haemophilia: carrier detection and prenatal diagnosis. (1993) (108)
Molecular basis of von Willebrand disease type IIB. Candidate mutations cluster in one disulfide loop between proposed platelet glycoprotein Ib binding sequences. (1991) (107)
Co‐morbidities and quality of life in elderly persons with haemophilia (2010) (106)
Spectrum of von Willebrand's Disease: a Study of 100 Cases (1977) (106)
Factor VIII gene (F8) mutations as predictors of outcome in immune tolerance induction of hemophilia A patients with high‐responding inhibitors (2009) (104)
Transmission of parvovirus B19 by coagulation factor concentrates exposed to 100°C heat after lyophilization (1997) (103)
Free Protein S Deficiency Is a Risk Factor for Venous Thrombosis (1997) (103)
DESMOPRESSIN AND THROMBOSIS (1989) (103)
Gene polymorphisms predicting high plasma levels of coagulation and fibrinolysis proteins. A study in centenarians. (1997) (102)
Acquired haemophilia A: A 2013 update (2013) (101)
Outbreak of hepatitis A among Italian patients with haemophilia (1992) (101)
Prophylaxis in severe forms of von Willebrand's disease: results from the von Willebrand Disease Prophylaxis Network (VWD PN) (2013) (101)
The Italian AICE-Genetics hemophilia A database: results and correlation with clinical phenotype (2008) (101)
Pregnancy in women with different types of von Willebrand disease. (1986) (101)
Biochemical and Metabolic Aspects of Platelet Dysfunction in Chronic Myeloproliferative Disorders (1982) (100)
Laboratory control of oral anticoagulant treatment by the INR system in patients with the antiphospholipid syndrome and lupus anticoagulant. Results of a collaborative study involving nine commercial thromboplastins (2001) (100)
Treatment of severe von Willebrand disease with a high‐purity von Willebrand factor concentrate (Wilfactin®): a prospective study of 50 patients (2007) (100)
Impact on human health of climate changes. (2015) (99)
Markers of Procoagulant Imbalance in Patients with Inherited Thrombophilic Syndromes (1992) (98)
Factor VIII products and inhibitor development: the SIPPET study (survey of inhibitors in plasma‐product exposed toddlers) (2007) (97)
Released adenosine diphosphate stabilizes thrombin-induced human platelet aggregates. (1990) (97)
Circulating microparticles and risk of venous thromboembolism. (2009) (97)
Pharmacokinetics and safety of fibrinogen concentrate (2009) (97)
Pattern of symptoms in 93 Iranian patients with severe factor XIII deficiency (2003) (97)
Platelets: an update on diagnosis and management of thrombocytopenic disorders. (2001) (96)
Hemophilia therapy: the future has begun (2020) (96)
A sensitive ristocetin co-factor activity assay with recombinant glycoprotein Ibalpha for the diagnosis of patients with low von Willebrand factor levels. (2004) (95)
An investigation of three patients with Christmas disease due to an abnormal type of factor ix (1968) (95)
The first ambulatory screening on thromboembolism: a multicentre, cross‐sectional, observational study on risk factors for venous thromboembolism (2005) (94)
The Effect of Desmopressin on Reducing Blood Loss in Cardiac Surgery – A Meta-Analysis of Double-Blind, Placebo-Controlled Trials (1995) (94)
Inhibitors of propagation of coagulation (factors VIII, IX and XI): a review of current therapeutic practice. (2011) (94)
Thrombin generation in plasma from patients with cirrhosis supplemented with normal plasma: considerations on the efficacy of treatment with fresh-frozen plasma (2012) (94)
Fibrinolytic shut‐down after surgery: impairment of the balance between tissue‐type plasminogen activator and its specific inhibitor (1985) (93)
CORRECTION OF ABNORMAL COAGULATION IN CHRONIC LIVER DISEASE BY COMBINED USE OF FRESH-FROZEN PLASMA AND PROTHROMBIN COMPLEX CONCENTRATES (1976) (93)
Clinical manifestations in 28 Italian and Iranian patients with severe factor VII deficiency (1997) (93)
Classic thrombophilic gene variants (2015) (93)
Activation of the coagulation cascade after infusion of a factor XI concentrate in congenitally deficient patients. (1994) (92)
Oral surgery in patients on oral anticoagulant therapy: a randomized comparison of different intensity targets. (2007) (92)
Prospective Multicenter Study on Subcutaneous Concentrated Desmopressin for Home Treatment of Patients with von Willebrand Disease and Mild or Moderate Hemophilia A (1996) (92)
Measurement of von Willebrand factor cleaving protease (ADAMTS‐13): results of an international collaborative study involving 11 methods testing the same set of coded plasmas (2004) (92)
A factor V genetic component differing from factor V R506Q contributes to the activated protein C resistance phenotype (1997) (92)
Abnormal hemostasis tests and bleeding in chronic liver disease: are they related? No (2006) (90)
Low Prevalence of Factor V:Q506 in 41 Patients with Isolated Pulmonary Embolism (1997) (89)
Low Prevalence of the Factor V Leiden Mutation Among “Severe” Hemophiliacs with a “Milder” Bleeding Diathesis (1995) (89)
Thrombotic adverse events to coagulation factor concentrates for treatment of patients with haemophilia and von Willebrand disease: a systematic review of prospective studies (2012) (89)
Hemophilia and related bleeding disorders: a story of dismay and success. (2002) (89)
The risk of recurrent venous thromboembolism among heterozygous carriers of the G20210A prothrombin gene mutation (2001) (88)
Factors influencing the long‐term outcome of primary total knee replacement in haemophiliacs: a review of 116 procedures at a single institution (2009) (88)
Markers of activation of coagulation and fibrinolysis in patients with Cushing’s syndrome (2000) (88)
Randomized controlled trial of desmopressin plus terlipressin vs. terlipressin alone for the treatment of acute variceal hemorrhage in cirrhotic patients: A multicenter, double‐blind study (1993) (87)
Clinical evaluation of moroctocog alfa (AF‐CC), a new generation of B‐domain deleted recombinant factor VIII (BDDrFVIII) for treatment of haemophilia A: demonstration of safety, efficacy, and pharmacokinetic equivalence to full‐length recombinant factor VIII (2009) (86)
Seasonal and monthly variability in the incidence of venous thromboembolism (2011) (86)
Intravenous and Subcutaneous Administration of Desmopresssin (DDAVP) to Hemophiliacs: Pharmacokinetics and Factor VIII Responses (1987) (86)
Embryo implantation after assisted reproductive procedures and maternal thrombophilia. (2003) (86)
Laboratory Screening of Inherited Thrombotic Syndromes (1987) (85)
Safety Profile of Porcine Factor VIII and Its Use as Hospital and Home-Therapy for Patients with Haemophilia-A and Inhibitors: the Results of An International Survey (1996) (85)
Shear-induced platelet aggregation is potentiated by desmopressin and inhibited by ticlopidine. (1993) (85)
Risk Factors for Deep Venous Thrombosis of the Upper Extremities (1997) (85)
A randomized, double-blind comparison of two dosage levels of recombinant factor VIIa in the treatment of joint, muscle and mucocutaneous haemorrhages in persons with haemophilia A and B, with and without inhibitors. rFVIIa Study Group. (1998) (84)
Air Pollution, Smoking, and Plasma Homocysteine (2006) (84)
Clinical Evaluation of Viral Safety of Coagulation Factor VIII and IX Concentrates (1993) (83)
Effect of tamoxifen on measurements of hemostasis in healthy women. (1996) (83)
Molecular Characterisation and Three-Dimensional Structural Analysis of Mutations in 21 Unrelated Families with Inherited Factor VII Deficiency (2000) (83)
Immune tolerance induction with a high purity von Willebrand factor/VIII complex concentrate in haemophilia A patients with inhibitors at high risk of a poor response (2007) (83)
Evidence-based recommendations on the treatment of von Willebrand disease in Italy. (2009) (83)
Safety of intravenous tranexamic acid in patients undergoing majororthopaedic surgery: a meta-analysis of randomised controlled trials. (2018) (83)
Controlled trial of desmopressin in liver cirrhosis and other conditions associated with a prolonged bleeding time. (1986) (83)
Venous and arterial thrombosis: different sides of the same coin? (2008) (82)
Alterations of Factor VIII von Willebrand Factor in Clinical Conditions Associated with an Increase in its Plasma Concentration (1981) (82)
VIRUCIDAL TREATMENT OF CLOTTING FACTOR CONCENTRATES (1988) (82)
Procoagulant imbalance in patients with non-alcoholic fatty liver disease. (2014) (82)
High levels of factor VIII and risk of extra-hepatic portal vein obstruction. (2009) (81)
Italian Registry of Haemophilia and Allied Disorders. Objectives, methodology and data analysis (2008) (81)
DDAVP shortens the prolonged bleeding times of patients with severe von Willebrand disease treated with cryoprecipitate. Evidence for a mechanism of action independent of released von Willebrand factor (1989) (81)
Haemophilia: strategies for carrier detection and prenatal diagnosis. (1993) (81)
Thrombin generation is not increased in the blood of hemophilia B patients after the infusion of a purified factor IX concentrate. (1990) (81)
Anti‐beta 2 glycoprotein I antibodies and the risk of myocardial infarction in young premenopausal women (2007) (80)
Congenital afibrinogenemia: mutations leading to premature termination codons in fibrinogen A alpha-chain gene are not associated with the decay of the mutant mRNAs. (2001) (80)
Alloantibodies in von Willebrand disease. (2013) (80)
Risk factors for hospital readmission of elderly patients. (2013) (79)
Safety and immunogenicity of HIV-1 Tat toxoid in immunocompromised HIV-1-infected patients. (1998) (79)
Deficiency of (33P)2MeS-ADP Binding Sites on Platelets with Secretion Defect, Normal Granule Stores and Normal Thromboxane A2 Production (1997) (78)
Atherosclerosis and von Willebrand factor (1984) (78)
Human recombinant DNA‐derived antihemophilic factor in the treatment of previously untreated patients with hemophilia A: final report on a hallmark clinical investigation (2004) (78)
Initial experience from a double‐blind, placebo‐controlled, clinical outcome study of ARC1779 in patients with thrombotic thrombocytopenic purpura (2012) (78)
Naturally occurring anticoagulants and bone marrow transplantation: plasma protein C predicts the development of venocclusive disease of the liver (1993) (77)
Ticlopidine Selectively Inhibits Human Platelet Responses to Adenosine Diphosphate (1991) (77)
Pharmacokinetic studies on Wilfactin®, a von Willebrand factor concentrate with a low factor VIII content treated with three virus‐inactivation/removal methods (2005) (77)
Replacement Therapy with Virus—Inactivated Plasma Concentrates in von Willebrand Disease (1992) (77)
Italian guidelines for the diagnosis and treatment of patients with haemophilia and inhibitors (2005) (77)
Clinical indications for desmopressin (DDAVP) in congenital and acquired von Willebrand disease. (1991) (76)
Von Willebrand Disease Type 2M “Vicenza” in Italian and German Patients: Identification of the First Candidate Mutation (G3864A; R1205H) in 8 Families (2000) (76)
Particulate air pollution and cardiovascular risk: short-term and long-term effects. (2009) (75)
Antibodies to tissue-type plasminogen activator (tPA) in patients with antiphospholipid syndrome: evidence of interaction between the antibodies and the catalytic domain of tPA in 2 patients. (2004) (75)
Clinical use of Haemate P in inherited von Willebrand's disease: a cohort study on 100 Italian patients. (2007) (75)
Controlled trial of streptokinase and heparin in acute myocardial infarction. (1971) (75)
Attitudes towards polypharmacy and medication withdrawal among older inpatients in Italy (2016) (74)
Use of Porcine Factor VIII in the Management of Seventeen Patients with Factor VIII Antibodies (1984) (74)
Delta infection and liver disease in hemophilic carriers of hepatitis B surface antigen. (1982) (74)
Rotational thromboelastography for monitoring of fibrinogen concentrate therapy in fibrinogen deficiency (2008) (74)
Factor VIII-related properties in platelets from patients with von Willebrand's disease. (1978) (74)
Screening for the FV: Q506 Mutation – Evaluation of Thirteen Plasma-based Methods for their Diagnostic Efficacy in Comparison with DNA Analysis (1997) (73)
How we choose factor VIII to treat hemophilia. (2012) (73)
Hepatocellular carcinoma in hemophilia (1991) (73)
Low Plasma Levels of Vitamin B6 Are Independently Associated With a Heightened Risk of Deep-Vein Thrombosis (2001) (73)
EUHASS: The European Haemophilia Safety Surveillance system. (2011) (73)
Hypercoagulability in splenectomized thalassemic patients detected by whole-blood thromboelastometry, but not by thrombin generation in platelet-poor plasma (2009) (73)
The endogenous thrombin potential and the risk of venous thromboembolism. (2007) (72)
Coinheritance of the HR2 haplotype in the factor V gene confers an increased risk of venous thromboembolism to carriers of factor V R506Q (factor V Leiden). (1999) (72)
Molecular Characterization of a Multiethnic Group of 21 Patients with Type 3 von Willebrand Disease (2000) (72)
Additional genetic risk factors for venous thromboembolismin carriers of the factor V Leiden mutation (1998) (71)
Interaction of porcine von Willebrand factor with the platelet glycoproteins Ib and IIb/IIIa complex (1992) (71)
Precipitating antibodies to factor VIII/von Willebrand factor in von Willebrand's disease: effects on replacement therapy. (1981) (71)
Gene mutations and three‐dimensional structural analysis in 13 families with severe factor X deficiency (2002) (71)
Coinheritance of the HR2 Haplotype in the Factor V Gene Confers an Increased Risk of Venous Thromboembolism to Carriers of Factor V R506Q (Factor V Leiden) (1999) (71)
The management of hemophilia in elderly patients (2007) (70)
Is haemophilia B less severe than haemophilia A? (2013) (70)
Laboratory Diagnosis of Lupus Anticoagulants for Patients on Oral Anticoagulant Treatment (2002) (69)
Life‐threatening reaction to factor VIII concentrate in a patient with severe von Willebrand disease and alloantibodies to von Willebrand factor (1987) (69)
Normal thrombin generation in neonates in spite of prolonged conventional coagulation tests (2008) (69)
Mutant factor V (Arg506Gln) in healthy centenarians (1996) (69)
Pharmacokinetics of Monoclonally-Purified and Recombinant Factor VIII in Patients with Severe von Willebrand Disease (1993) (68)
The Factor‐X Defect: Recognition of Abnormal Forms of Factor X (1970) (68)
Identification and Three-dimensional Structural Analysis of Nine Novel Mutations in Patients with Prothrombin Deficiency (2000) (68)
Randomized controlled trial of desmopressin plus terlipressin vs. terlipressin alone for the treatment of acute variceal hemorrhage in cirrhotic patients: a multicenter, double-blind study. New Italian Endoscopic Club. (1993) (68)
Abnormalities of hemostasis and bleeding in chronic liver disease: the paradigm is challenged (2010) (68)
Von Willebrand disease‐associated angiodysplasia: a few answers, still many questions (2013) (67)
The Post-thrombotic Syndrome in Young Women: Retrospective Evaluation of Prognostic Factors (1998) (67)
Venous thromboembolism in acute stroke. Prognostic importance of hypercoagulability. (1992) (67)
High Frequency of the C677T Mutation in the Methylenetetrahydrofolate Reductase (MTHFR) Gene in Northern Italy (1997) (66)
Hemostasis Abnormalities in Patients with Vascular Dementia and Alzheimer’s Disease (1996) (66)
Low borderline plasma levels of antithrombin, protein C and protein S are risk factors for venous thromboembolism (2012) (66)
Factor IXa-factor VIIIa-cell surface complex does not contribute to the basal activation of the coagulation mechanism in vivo. (1992) (66)
CONGENITAL DEFICIENCY OF THROMBOXANE AND PROSTACYCLIN (1980) (66)
Hypercoagulability in acute stroke (1987) (66)
Thrombogenic potential of human coronary atherosclerotic plaques. (2001) (65)
A 23bp Insertion in the Endothelial Protein C Receptor (EPCR) Gene Impairs EPCR Function (2001) (65)
Adherence to antithrombotic therapy guidelines improves mortality among elderly patients with atrial fibrillation: insights from the REPOSI study (2016) (65)
Liver dysfunction rather than intravascular coagulation as the main cause of low protein C and antithrombin III in acute leukemia (1984) (65)
Molecular basis of fibrinogen Naples associated with defective thrombin binding and thrombophilia. Homozygous substitution of B beta 68 Ala----Thr. (1992) (65)
TTP and ADAMTS13: When Is Testing Appropriate? (2007) (64)
Subcutaneous desmopressin (DDAVP) shortens the bleeding time in uremia (1989) (64)
Identification of differentially expressed genes in coronary atherosclerotic plaques from patients with stable or unstable angina by cDNA array analysis (2003) (64)
Use of desmopressin (DDAVP) during early pregnancy in factor VIII-deficient women. (2005) (64)
Deep intronic variations may cause mild hemophilia A (2011) (63)
Rare bleeding disorders (2006) (63)
Patients With Type 3 Severe von Willebrand Disease Are Not Protected Against Atherosclerosis: Results From a Multicenter Study in 47 Patients (2004) (63)
Association between venous and arterial thrombosis: clinical implications. (2012) (63)
Factor VIII antigen in the vessel walls in von Willebrand's disease and haemophilia A. (2009) (63)
The JAK2 V617F mutation in patients with cerebral venous thrombosis (2012) (63)
Low Levels of Heparin-releasable Tissue Factor Pathway Inhibitor in Young Patients with Thrombosis (1999) (63)
Treatment of congenital antithrombin III deficiency with concentrates (1982) (62)
Novel evidence for a greater burden of ambient air pollution on cardiovascular disease (2019) (62)
Inhibitor development in previously treated hemophilia A patients: a systematic review, meta‐analysis, and meta‐regression (2013) (62)
Atypical hemolytic uremic syndrome (aHUS): essential aspects of an accurate diagnosis. (2016) (61)
Low platelet alpha2beta1 levels in type I von Willebrand disease correlate with impaired platelet function in a high shear stress system. (1999) (61)
Gastrointestinal angiodysplasia and bleeding in von Willebrand disease (2014) (61)
Drug–drug interactions in a cohort of hospitalized elderly patients (2013) (61)
Plasminogen activator response after DDAVP: a clinico-pharmacological study. (1980) (60)
Risk factors for postpartum hemorrhage in a cohort of 6011 Italian women. (2012) (60)
Coagulation activation and long-term outcome in acute coronary syndromes. (2003) (60)
Silica clotting time (SCT) as a screening and confirmatory test for detection of the lupus anticoagulants. (1992) (60)
No activation of the common pathway of the coagulation cascade after a highly purified factor IX concentrate (1991) (59)
How I treat rare venous thromboses. (2008) (59)
Factor VIII replacement is still the standard of care in haemophilia A. (2019) (59)
A Multicenter Controlled, Randomized, Open Trial of Interferon α2b Treatment of Anti–Human Immunodeficiency Virus-Negative Hemophilic Patients With Chronic Hepatitis C (1997) (59)
Factor V Leiden and G20210A prothrombin mutation and the risk of subclavian vein thrombosis in patients with breast cancer and a central venous catheter. (2004) (58)
Oral contraceptive use, thrombophilia and their interaction in young women with ischemic stroke. (2006) (58)
Acquired storage pool disease in platelets during disseminated intravascular coagulation. (1976) (58)
Short-term Exposure to High Altitude Causes Coagulation Activation and Inhibits Fibrinolysis (2002) (58)
Defining Aging Phenotypes and Related Outcomes: Clues to Recognize Frailty in Hospitalized Older Patients (2016) (58)
Degradation of von Willebrand factor in patients with acquired clinical conditions in which there is heightened proteolysis. (1993) (58)
Hemostatic balance in patients with liver cirrhosis: Report of a consensus conference. (2016) (58)
Molecular and phenotypic determinants of the response to desmopressin in adult patients with mild hemophilia A (2009) (58)
Exercise training in mild hypertension: effects on blood pressure, left ventricular mass and coagulation factor VII and fibrinogen. (1997) (58)
Type and location of venous thromboembolism in patients with factor V Leiden or prothrombin G20210A and in those with no thrombophilia (2007) (58)
Patients with localized and disseminated tumors have reduced but measurable levels of ADAMTS-13 (von Willebrand factor cleaving protease). (2003) (58)
Second international collaborative study evaluating performance characteristics of methods measuring the von Willebrand factor cleaving protease (ADAMTS‐13) (2008) (58)
Correction of the bleeding time in treated patients with severe von willebrand disease is not solely dependent on the normal multimeric structure of plasma von willebrand factor (1987) (58)
Old and new anticoagulant drugs: A minireview (2011) (58)
A prothrombin time-based functional assay of protein S. (1990) (58)
Thrombo-Inflammation in Cardiovascular Disease: An Expert Consensus Document from the Third Maastricht Consensus Conference on Thrombosis (2020) (58)
Liver dysfunction rather than intravascular coagulation as the main cause of low protein C and antithrombin III in acute leukemia. (1984) (58)
Protein C Antigen Is Not an Acute Phase Reactant and Is often High in Ischemic Heart Disease and Diabetes (1984) (58)
Heightened Thrombin Generation in Individuals with Resistance to Activated Protein C (1996) (58)
A new era for anticoagulants. (2009) (57)
Thrombin and Cancer: From Molecular Basis to Therapeutic Implications (2012) (57)
Intracranial haemorrhage in the Italian population of haemophilia patients with and without inhibitors (2012) (57)
A multicenter pharmacokinetic study of the B‐domain deleted recombinant factor VIII concentrate using different assays and standards (2003) (57)
The thrombospondin-1 N700S polymorphism is associated with early myocardial infarction without altering von Willebrand factor multimer size. (2006) (57)
von Willebrand factor cleaving protease ( ADAMTS 13 ) is deficient in recurrent and familial thrombotic thrombocytopenic purpura and hemolytic uremic syndrome (2002) (56)
Factor VIII: C increases after desmopressin in a subgroup of patients with autosomal recessive severe von Willebrand disease (1995) (56)
Low risk for hepatitis C in hemophiliacs given a high-purity, pasteurized factor VIII concentrate. International Study Group. (1990) (56)
Low risk of viral infection after administration of vapor‐heated factor VIII concentrate (1992) (56)
Analysis of the tissue factor pathway inhibitor gene and antigen levels in relation to venous thrombosis (2001) (56)
Identification of nine novel mutations in type I antithrombin deficiency by heteroduplex screening (1993) (55)
Molecular analysis of the genotype-phenotype relationship in factor X deficiency (2000) (55)
Platelets and the vessel wall: how much aspirin? (1980) (55)
The association of factor V Leiden with myocardial infarction is replicated in 1880 patients with premature disease (2010) (55)
Fibrinogen assays: a collaborative study of six different methods. C.I.S.M.E.L. Comitato Italiano per la Standardizzazione dei Metodi in Ematologia e Laboratorio. (1991) (54)
Incidence of severe von Willebrand's disease. (1982) (54)
Reduction in transmission of hepatitis C after the introduction of a heat‐treatment step in the production of C1‐inhibitor concentrate (1995) (54)
Phenotype‐genotype characterization of 10 families with severe a subunit factor XIII deficiency (2004) (54)
Factor V (Arg506⟶ Gln) Mutation in Young Survivors of Myocardial Infarction (1996) (53)
International Collaborative Study for the Calibration of a Proposed Reference Preparation for Thromboplastin, Human Recombinant, Plain (1998) (53)
Factor XI deficiency in Iranians: its clinical manifestations in comparison with those of classic hemophilia. (2002) (53)
Source and purity of factor VIII products as risk factors for inhibitor development in patients with hemophilia A (2012) (53)
Inhibitors to Factor VIII in a Family with Mild Hemophilia: Molecular Characterization and Response to Factor VIII and Desmopressin (1995) (53)
Inhibitor eradication with rituximab in haemophilia: where do we stand? (2014) (52)
Multicenter Study of Homocysteine Measurement – Performance Characteristics of Different Methods, Influence of Standards on Interlaboratory Agreement of Results (2001) (52)
Effects of PCSK9 genetic variants on plasma LDL cholesterol levels and risk of premature myocardial infarction in the Italian population (2010) (52)
Near‐patient testing devices to monitor oral anticoagulant therapy (2001) (52)
Hemostatic defects in liver and renal dysfunction. (2012) (52)
Protein C in acute stroke. (1988) (52)
Role of Chloride Ions in Modulation of the Interaction between von Willebrand Factor and ADAMTS-13* (2005) (52)
Formation of methionine sulfoxide by peroxynitrite at position 1606 of von Willebrand factor inhibits its cleavage by ADAMTS-13: A new prothrombotic mechanism in diseases associated with oxidative stress. (2010) (51)
Different clinical severity of first episodes and recurrences of thrombotic thrombocytopenic purpura (2010) (51)
Low-Dose Heparin and Deep-Vein Thrombosis after Total Hip Replacement (1976) (51)
Protein S Deficiency Associated with “Juvenile” Arterial and Venous Thromboses (1986) (51)
Familial Dysfunction of Protein S (1989) (51)
Opposite changes of ADAMTS‐13 and von Willebrand factor after cardiac surgery (2005) (51)
Risk of thromboembolic complications in patients with inflammatory bowel disease (1992) (51)
Asymptomatic homozygous protein C deficiency. (1990) (50)
Desmopressin, Surgery and Thrombosis (1994) (50)
Genetic control of anticoagulation (1999) (50)
Subcutaneous Desmopressin (DDAVP) Shortens the Prolonged Bleeding Time in Patients with Liver Cirrhosis (1990) (50)
Low protein C in the neonatal period (1986) (50)
Ndufc2 Gene Inhibition Is Associated With Mitochondrial Dysfunction and Increased Stroke Susceptibility in an Animal Model of Complex Human Disease (2016) (49)
Precipitating antibodies in von Willebrand's disease (1976) (49)
Management of inherited von Willebrand disease in Italy: results from the retrospective study on 1234 patients. (2011) (49)
The role of thrombophilia in splanchnic vein thrombosis. (2008) (49)
Immune tolerance induction with recombinant factor VIII in hemophilia A patients with high responding inhibitors. (2006) (49)
Effects on bleeding complications of pharmacogenetic testing for initial dosing of vitamin K antagonists: a systematic review and meta‐analysis (2014) (49)
Factor VII Clotting Assay: Influence of Different Thromboplastins and Factor VII-Deficient Plasmas (1991) (48)
New anticoagulants for treatment of venous thromboembolism. (2012) (48)
Long-Term Relationship Between Atrial Fibrillation, Multimorbidity and Oral Anticoagulant Drug Use. (2019) (48)
Changes in clinical outcomes for community‐dwelling older people exposed to incident chronic polypharmacy: a comparison between 2001 and 2009 (2016) (47)
Heightened thrombin formation but normal plasma levels of activated factor VII in patients with acute coronary syndromes. (1995) (47)
ReFacto® 1 and Advate® 2 : a single‐dose, randomized, two‐period crossover pharmacokinetics study in subjects with haemophilia A (2007) (47)
Suboptimal response to hepatitis B vaccine in drug users. (1991) (47)
Desmopressin (DDAVP) for treatment of disorders of hemostasis. (1986) (47)
Efficacy and inhibitor development in previously treated patients with haemophilia A switched to a B domain‐deleted recombinant factor VIII (2004) (47)
Germinal Matrix Hemorrhage: Intraventricular Hemorrhage in Very-Low-Birth-Weight Infants The Independent Role of Inherited Thrombophilia (2011) (47)
Tamoxifen reduces plasma homocysteine levels in healthy women. (1998) (47)
Pharmacokinetic Properties of Recombinant Factor VIII Compared with a Monoclonally Purified Concentrate (Hemofil® M) (1992) (47)
Congenital plasminogen deficiency associated with venous thromboembolism: therapeutic trial with stanozolol (1986) (46)
The relationship between plasma homocysteine levels and bone mineral density in post-menopausal women. (2010) (46)
Different Quantitative Apoptotic Traits in Coronary Atherosclerotic Plaques From Patients With Stable Angina Pectoris and Acute Coronary Syndromes (2004) (46)
Polypharmacy in older people: lessons from 10 years of experience with the REPOSI register (2018) (46)
Genetic hypercoagulability: prevention suggests testing family members. (2001) (46)
Carrier detection in hemophilia A: a cooperative international study. I. The carrier phenotype. (1986) (46)
Acquired von Willebrand syndrome: focused for hematologists (2020) (45)
Treatment of Congenital Factor VII Deficiency with a New Concentrate (1978) (45)
Diagnosis and management of von Willebrand disease (1999) (45)
Effects of CYP2C9 and VKORC1 on INR variations and dose requirements during initial phase of anticoagulant therapy. (2008) (45)
Determination of the International Sensitivity Index of a New Near-Patient Testing Device to Monitor Oral Anticoagulant Therapy (1997) (45)
Low levels of protein Z and the risk of venous thromboembolism (2005) (45)
Standard Nomenclature for Factor VIII and von Willebrand Factor: A Recommendation by the International Committee on Thrombosis and Haemostasis (1985) (45)
Value of Normotest and antithrombin 3 in the assessment of liver function. (1973) (44)
Characterization of two cases of acquired transitory von willebrand syndrome with ciprofloxacin: Evidence for heightened proteolysis of von willebrand factor (1995) (44)
Revision of the Protocol Recommended for Studies of Safety from Hepatitis of Clotting Factor Concentrates (1989) (44)
Platelet aggregation at high shear is impaired in patients with congenital defects of platelet secretion and is corrected by DDAVP: correlation with the bleeding time. (1995) (44)
von Willebrand factor synthesized by endothelial cells from a patient with type IIB von Willebrand disease supports platelet adhesion normally but has an increased affinity for platelets. (1989) (43)
Hemodialysis without anticoagulants: efficiency and hemostatic aspects. (1984) (43)
Venous thrombosis and anticoagulant therapy (2001) (43)
Another Protein S Functional Assay Is Sensitive to Resistance to Activated Protein C (1994) (43)
Assessment of the Influence of Citrate Concentration on the International Normalized Ratio (INR) Determined with Twelve Reagent-instrument Combinations (1998) (43)
Modern Treatment of Hemophilia: From the Shadows Towards the Light (1993) (43)
Determination of total homocysteine in plasma: comparison of the Abbott IMx immunoassay with high performance liquid chromatography. (2002) (43)
Absence of clinical, virological, and immunological signs of progression in HIV-1-infected patients receiving active anti-interferon-alpha immunization: a 30-month follow-up report. (1996) (43)
The role of platelet von Willebrand factor in platelet adhesion and thrombus formation: a study of 34 patients with various subtypes of type I von Willebrand disease (1994) (43)
Non-factor replacement therapy for haemophilia: a current update. (2018) (43)
Coagulation activation and long-term outcome in acute coronary syndromes Running title: Coagulation activation and long-term outcome in CHD Section heading: Clinical observation (2003) (42)
A prospective multicenter study of hepatocellular carcinoma in italian hemophiliacs with chronic hepatitis C. The Study Group of the Association of Italian Hemophilia Centers. (1998) (42)
The natural history of occult or angiodysplastic gastrointestinal bleeding in von Willebrand disease (2015) (42)
Absence of hyperhomocysteinemia in ten patients with primary pulmonary hypertension. (1997) (42)
Markers of activated coagulation and their usefulness in the clinical laboratory. (1996) (42)
Familial incidence of precipitating antibodies in von Willebrand's disease: a study of four cases. (1979) (42)
COVID-19 Vaccine and Death: Causality Algorithm According to the WHO Eligibility Diagnosis (2021) (42)
Cardiovascular disease in haemophilia patients: a contemporary issue (2010) (42)
Mitigation of air pollution by greenness: A narrative review. (2018) (42)
Advantages and limits of ADAMTS13 testing in thrombotic thrombocytopenic purpura. (2008) (42)
Treatment of von Willebrand disease (1998) (42)
Transmission of parvovirus B19 by coagulation factor concentrates exposed to 100 degrees C heat after lyophilization. (1997) (42)
Outcome of Treatment of Deep-Vein Thrombosis with Urokinase: Relationship to Dosage, Duration of Therapy, Age of the Thrombus and Laboratory Changes (1984) (42)
Tissue plasminogen activator antigen is strongly associated with myocardial infarction in young women (2005) (42)
Desmopressin: a nontransfusional hemostatic agent. (1990) (42)
Effects of Hirudin on Activated Partial Thromboplastin Time Determined with Ten Different Reagents (1993) (42)
Failure of recombinant activated factor VII during surgery in a hemophiliac with high-titer factor VIII antibody. (1991) (42)
Lupus anticoagulants and their relationship with the inhibitors against coagulation factor VIII: considerations on the differentiation between the 2 circulating anticoagulants. (2005) (42)
High Plasma Levels of Protein C Activity and Antigen in the Nephrotic Syndrome (1986) (42)
Immune Status of Asymptomatic HIV-Infected Hemophiliacs: Randomized, Prospective, Two-Year Comparison of Treatment with a High-Purity or an Intermediate-Purity Factor VIII Concentrate (1992) (41)
Storage Pool Disease: Comparative Fluorescence Microscopical, Cytochemical and Biochemical Studies on Amine‐Storing Organelles of Human Blood Platelets (1979) (41)
Association and Functional Analyses of MEF2A as a Susceptibility Gene for Premature Myocardial Infarction and Coronary Artery Disease (2009) (41)
Prevention of hemoperitoneum during ovulation by oral contraceptives in women with type III von Willebrand disease and afibrinogenemia. Case reports. (1991) (41)
Genetic risk stratification to reduce inhibitor development in the early treatment of hemophilia A: a SIPPET analysis. (2017) (41)
Value of Hu antibody determinations in the follow-up of paraneoplastic neurologic syndromes (2004) (41)
Patient preferences and willingness to pay for different options of anticoagulant therapy (2013) (41)
Comparison of Functional Assays for Protein S: European Collaborative Study of Patients with Congenital and Acquired Deficiency (1993) (41)
Venous thrombosis: the history of knowledge (2002) (40)
TT virus is present in a high frequency of Italian hemophilic patients transfused with plasma-derived clotting factor concentrates. (1999) (40)
Desmopressin and blood loss after cardiac surgery (1993) (40)
Post-mortem findings in vaccine-induced thrombotic thrombocytopenia (2021) (40)
Hemolytic uremic syndrome in adults. (1980) (40)
Hyper‐responsiveness to DDAVP for patients with type I von Willebrand's disease and normal intra‐platelet von Willebrand factor (1988) (39)
In vitro effects of picotamide on human platelet aggregation, the release reaction and thromboxane B2 production. (1991) (39)
Plasma-derived versus recombinant factor VIII concentrates for the treatment of haemophilia A: plasma-derived is better. (2010) (39)
Hyperhomocysteinemia as a risk factor for deep-vein thrombosis. (1996) (39)
Kreuth III: European consensus proposals for treatment of haemophilia with coagulation factor concentrates (2014) (39)
Protein C Antigen During Pregnancy, Delivery and Puerperium (1984) (39)
Prospective study of the evaluation of hepatitis C virus infectivity in a high‐purity, solvent/detergent‐treated factor VIII concentrate: parallel evaluation of other markers for lipid‐enveloped and non‐lipid‐ enveloped viruses. (1993) (39)
The international normalized ratio to prioritize patients for liver transplantation: problems and possible solutions. (2008) (39)
Prevalence of Infection with the Hepatitis C Virus among Italian Hemophiliacs before and after the Introduction of Virally Inactivated Clotting Factor Concentrates: A Retrospective Evaluation (1994) (39)
TTP and ADAMTS 13 : When Is Testing Appropriate ? (2007) (39)
Identification of genetic risk variants for deep vein thrombosis by multiplexed next-generation sequencing of 186 hemostatic/pro-inflammatory genes (2012) (39)
Long‐term safety and feasibility of arteriovenous fistulae as vascular accesses in children with haemophilia: a prospective study (2003) (39)
Platelet von willebrand factor abnormalities in myeloproliferative syndromes (1995) (39)
Activation of the contact system and inflammation after thrombolytic therapy in patients with acute myocardial infarction. (2004) (39)
Naturally occurring anticoagulants and bone marrow transplantation: plasma protein C predicts the development of venocclusive disease of the liver. (1993) (39)
Detection of the prethrombotic state due to procoagulant imbalance (1992) (38)
Plasma levels of activated protein C in healthy subjects and patients with previous venous thromboembolism: relationships with plasma homocysteine levels. (1998) (38)
A Type 2b von Willebrand Disease Mutation (lle546→Val) Associated with an Unusual Phenotype (1997) (38)
Multicentric Evaluation of a New PT Reagent Based on Recombinant Human Tissue Factor and Synthetic Phospholipids (1994) (38)
MPL and JAK2 exon 12 mutations in patients with the Budd-Chiari syndrome or extrahepatic portal vein obstruction. (2008) (38)
Nonneutralizing antibodies against factor VIII and risk of inhibitor development in severe hemophilia A. (2017) (38)
The risk of first venous thromboembolism during pregnancy and puerperium in double heterozygotes for factor V Leiden and prothrombin G20210A (2008) (38)
Clinical and molecular characterization of 6 patients affected by severe deficiency of coagulation factor V: Broadening of the mutational spectrum of factor V gene and in vitro analysis of the newly identified missense mutations. (2003) (38)
A variant of von Willebrand's disease characterized by recessive inheritance and missing triplet structure of von Willebrand factor multimers (1983) (38)
Innovative Pharmacological Therapies for the Hemophilias Not Based on Deficient Factor Replacement (2016) (38)
Changes in bleeding patterns in von Willebrand disease after institution of long-term replacement therapy: results from the von Willebrand Disease Prophylaxis Network (2015) (38)
The History of Hemophilia (2014) (38)
Carrier detection in hemophilia A: a cooperative international study. II. The efficacy of a universal discriminant. (1986) (38)
Autosomal recessive deficiencies of coagulation factors. (2001) (37)
Early-onset ischaemic stroke: Analysis of 58 polymorphisms in 17 genes involved in methionine metabolism (2010) (37)
Liver disease, coagulopathies and transfusion therapy. (2013) (37)
Status of Present and Candidate International Reference Preparations (IRP) of Thromboplastin for the Prothrombin Time (1993) (37)
Multicenter Comparison of Five Functional and Two Immunological Assays for Protein C (1987) (37)
The genetic basis of coronary artery disease: from candidate genes to whole genome analysis. (2008) (37)
Efficacy and safety of highly purified, doubly virus‐inactivated VWF/FVIII concentrates in inherited von Willebrand’s disease: results of an Italian cohort study on 120 patients characterized by bleeding severity score (2010) (37)
Evaluation of prophylactic replacement therapy in haemophilia B. (2009) (37)
Screening test for thrombophilic patients: which tests, for which patient, by whom, when, and why? (1998) (37)
Investigation of a case of subtype IIC von Willebrand disease: Characterization of the variability of this subtype (1986) (36)
Congenital afibrinogenemia: intracellular retention of fibrinogen due to a novel W437G mutation in the fibrinogen Bbeta-chain gene. (2003) (36)
Association between particulate air pollution and venous thromboembolism: A systematic literature review. (2016) (36)
An Enzyme Immunoassay (ELISA) for the Quantitation of Human Factor VII (1986) (36)
Von Willebrand factor: another janus-faced hemostasis protein. (2008) (36)
Thrombomodulin Is a Cofactor for Thrombin Degradation of Recombinant Single-Chain Urokinase Plasminogen Activator "In Vitro" and in a Perfused Rabbit Heart Model (1992) (36)
Source of Factor VIII Replacement (PLASMATIC OR RECOMBINANT) and Incidence of Inhibitory Alloantibodies in Previously Untreated Patients with Severe Hemophilia a: The Multicenter Randomized Sippet Study (2015) (35)
Prothrombin Fragment 1+2 and Intensity of Treatment with Oral Anticoagulants (1991) (35)
Mechanisms, markers and management of coagulation activation. (1994) (35)
L-Asparaginase Lowers Protein C Antigen (1984) (35)
Significance of plasma fibrinopeptide A and high molecular weight fibrinogen in patients with liver cirrhosis (1982) (35)
The hemophilias: progress and problems. (1999) (35)
Relatively Poor Performance of Clinical Laboratories for DNA Analyses in the Detection of Two Thrombophilic Mutations – A Cause for Concern (2002) (35)
The role of the spleen in regulating the plasma levels of factor VIII--von Willebrand's factor after DDAVP. (1982) (34)
Solvent/detergent plasma for prevention of bleeding in recessively inherited coagulation disorders: dosing, pharmacokinetics and clinical efficacy. (2006) (34)
Sustained correction of the bleeding time in an afibrinogenaemic patient after infusion of fresh frozen plasma (1992) (34)
New antiplatelet agents: why they are needed. (2009) (34)
Antibody to hepatitis C virus after a vapour-heated factor VIII concentrate. The Study Group of the Fondazione dell'Emofilia. (1990) (34)
Effects of Oral Contraceptives and Obesity on Protein C Antigen (1985) (34)
The increase with age of the components of the tissue factor coagulation pathway is gender-dependent. (1995) (34)
Myocardial infarction in the young: a sex-based comparison (2007) (34)
Adverse clinical events and mortality during hospitalization and 3 months after discharge in cognitively impaired elderly patients. (2013) (33)
Molecular genetic analysis of severe coagulation factor XI deficiency in six Italian patients. (2004) (33)
Expression studies on a novel type 2B variant of the von Willebrand factor gene (R1308L) characterized by defective collagen binding (2005) (33)
Early presence of activated ('exhausted') platelets in malignant tumors (breast adenocarcinoma and malignant melanoma). (1989) (33)
Fibrinogen Milano II: A Congenital Dysfibrinogenaemia Associated with Juvenile Arterial and Venous Thrombosis (1986) (33)
Recombinant Tissue Factor as Substitute for Conventional Thromboplastin in the Prothrombin Time Test (1992) (33)
Homozygous protein C deficiency with moderately severe clinical symptoms. (1986) (33)
Short-term Evaluation of Synovectomy in Haemophilia (1972) (33)
Factor VII Deficiency: Immunological Characterization of Genetic Variants and Detection of Carriers (1981) (33)
Low Levels of the Anticoagulant Activity of Protein C in Patients with Chronic Renal Insufficiency: an Inhibitor of Protein C Is Present in Uremic Plasma (1991) (33)
A systematic overview of the first pasteurised VWF/FVIII medicinal product, Haemate®P/ Humate®‐P: History and clinical performance (2008) (33)
The natural mutation by deletion of Lys9 in the thrombin A‐chain affects the pKa value of catalytic residues, the overall enzyme's stability and conformational transitions linked to Na+ binding (2006) (32)
Feasibility of prophylaxis and immune tolerance induction regimens in haemophilic children using fully implantable central venous catheters (2008) (32)
Arg2074Cys missense mutation in the C2 domain of factor V causing moderately severe factor V deficiency: molecular characterization by expression of the recombinant protein. (2003) (32)
Thrombotic Thrombocytopenic Purpura: A Simpler Diagnosis at last? (1999) (32)
ADAMTS13 content in plasma‐derived factor VIII/von Willebrand factor concentrates (2013) (32)
Prothrombin A19911G polymorphism and the risk of venous thromboembolism (2006) (32)
A partial factor V deficiency in anticoagulated lyophilized plasmas has been identified as a cause of the international normalized ratio discrepancy in the external quality assessment scheme. (1995) (32)
Analysis of Iranian patients allowed the identification of the first truncating mutation in the fibrinogen Bbeta-chain gene causing afibrinogenemia. (2002) (32)
Proteolysis of von Willebrand factor is decreased in acute promyelocytic leukaemia by treatment with all‐trans‐retinoic acid (1996) (32)
No effect of polymorphisms in prothrombotic genes on the risk of myocardial infarction in young adults without cardiovascular risk factors (2005) (32)
Sustained suppression of hepatitis C virus by interferon and ribavirin in hemophilic patients not responding to interferon monotherapy. (2002) (32)
Afibrinogenemia: first identification of a splicing mutation in the fibrinogen gamma chain gene leading to a major gamma chain truncation. (2000) (32)
Characterization of fibrinogen Milano I: amino acid exchange gamma 330 Asp----Val impairs fibrin polymerization. (1986) (31)
The hemostatic system through aging and menopause (2009) (31)
Spontaneous platelet aggregation during pregnancy in a patient with von Willebrand disease type IIB can be blocked by monoclonal antibodies to both platelet glycoproteins Ib and IIb/IIIa (1990) (31)
Management of cerebral and splanchnic vein thrombosis associated with thrombocytopenia in subjects previously vaccinated with Vaxzevria (AstraZeneca): a position statement from the Italian Society for the Study of Haemostasis and Thrombosis (SISET). (2021) (31)
New concepts for anticoagulant therapy in persons with hemophilia. (2016) (31)
Factor VIII and chronic renal failure. (1977) (31)
A novel two base pair deletion in the factor V gene associated with severe factor V deficiency (2000) (31)
DDAVP shortens the prolonged bleeding times of patients with severe von Willebrand disease treated with cryoprecipitate. Evidence for a mechanism of action independent of released von Willebrand factor. (1989) (30)
AIDS, hepatitis and hemophilia in the 1980s: memoirs from an insider (2003) (30)
Desmopressin: Twenty Years After (1997) (30)
Antithrombin Milano, Single Amino Acid Substitution at the Reactive Site, Arg393 to Cys (1988) (30)
Low-molecular-weight heparins and cancer: Focus on antitumoral effect (2015) (30)
Nervous Regulation of Factor‐VIII Levels in Man (1971) (30)
Interaction Between the G 20210 A Mutation of the Prothrombin Gene and Oral Contraceptive Use in Deep Vein Thrombosis (1999) (30)
Tissue factor in human coronary atherosclerotic plaques. (2000) (29)
Increased production of platelet thromboxane B2 in non‐insulin‐dependent diabetes. Relationship to vascular complications (1984) (29)
Profound alterations of the multimeric structure of von Willebrand factor in a patient with malignant lymphoma (1985) (29)
Global coagulation in myeloproliferative neoplasms (2013) (29)
Laboratory detection of inherited thrombophilia: a historical perspective. (2005) (29)
Marburg I polymorphism of factor VII-activating protease and risk of venous thromboembolism. (2006) (29)
The Measurement of Multifactorial Thrombophilia (2002) (29)
Von Willebrand factor contaminating porcine factor VIII concentrate (Hyate: C) causes platelet aggregation (1986) (29)
SIPPET: methodology, analysis and generalizability (2017) (29)
Molecular and functional characterization of a natural homozygous Arg67His mutation in the prothrombin gene of a patient with a severe procoagulant defect contrasting with a mild hemorrhagic phenotype. (2002) (29)
Antithrombin Milano: a new variant with monomeric and dimeric inactive antithrombin III. (1985) (28)
Autoantibodies against the endothelial receptor of protein C are associated with acute myocardial infarction in young women (2005) (28)
Recent progress in the pathophysiology of fibrinogen. (1995) (28)
A Proposed Scheme for Calibration of International Reference Preparations of Thromboplastin for the Prothrombin Time (1995) (28)
Von Willebrand factor (Vonvendi®): the first recombinant product licensed for the treatment of von Willebrand disease (2016) (28)
HLA Antigens and Factor VIII Antibody in Classic Hemophilia (1981) (28)
High rates of hepatitis G virus infection in multitransfused patients with hemophilia. (1997) (28)
EVALUATION OF A FULLY AUTOMATED CENTRIFUGAL ANALYSER FOR ITS PERFORMANCE OF HEMOSTASIS TESTS (1987) (28)
Type I von Willebrand disease, subtype ‘platelet low’: decreased platelet adhesion can be explained by low synthesis of von Willebrand factor in endothelial cells (1993) (28)
Hyperprothrombinemia may result in acquired activated protein C resistance (2000) (28)
Advances in the genetics and treatment of von Willebrand disease. (2002) (28)
The complex differential diagnosis between thrombotic thrombocytopenic purpura and the atypical hemolytic uremic syndrome: Laboratory weapons and their impact on treatment choice and monitoring. (2015) (27)
Coexistence of a novel homozygous nonsense mutation in exon 13 of the factor V gene with the homozygous Leiden mutation in two unrelated patients with severe factor V deficiency (2001) (27)
Plasma factor VII levels are influenced by a polymorphism in the promoter region of the FVII gene (1996) (27)
E-learning in order to improve drug prescription for hospitalized older patients: a cluster-randomized controlled study. (2016) (27)
Uncertain thrombophilia markers (2016) (27)
Interactions between genotype and phenotype in bleeding and thrombosis (2008) (27)
Hypercoagulability and hyperfibrinolysis in patients with melanoma. (1996) (27)
Intramuscular anti‐D immunoglobulins for home treatment of chronic immune thrombocytopenic purpura (1992) (27)
Simultaneous genotyping of coagulation factor XI type II and type III mutations by multiplex real-time polymerase chain reaction to determine their prevalence in healthy and factor XI-deficient Italians (2008) (27)
Expression studies of missense mutations p.D141Y, p.C275S located in the propeptide of von Willebrand factor in patients with type 3 von Willebrand disease (2008) (27)
Resistance to activated protein C in unselected patients with arterial and venous thrombosis (1997) (27)
Timing and severity of inhibitor development in recombinant versus plasma‐derived factor VIII concentrates: a SIPPET analysis (2018) (27)
Low incidence of bleeding from HIV‐related thrombocytopenia in drug addicts and hemophiliacs: Implications for therapeutic strategies (1990) (27)
Markers of Hypercoagulability in Patients with Hemophilia B Given Repeated, Large Doses of Factor IX Concentrates during and after Surgery (1994) (27)
Direct oral anticoagulants and venous thromboembolism (2016) (26)
The European standards of Haemophilia Centres. (2014) (26)
Factor VIII clotting activity (1999) (26)
A rare inherited coagulation disorder: Combined homozygous factor VII and factor X deficiency (2004) (26)
Multicenter Comparison of von Willebrand Factor Multimer Sizing Techniques (1985) (26)
Presurgical pharmacokinetic analysis of a von Willebrand factor/factor VIII (VWF/FVIII) concentrate in patients with von Willebrand’s disease (VWD) has limited value in dosing for surgery (2011) (26)
Half-life extension technologies for haemostatic agents. (2014) (26)
Venocclusive disease of the liver after bone marrow transplantation: the role of hemostasis. (1997) (26)
Platelet von Willebrand factor assay: results using two methods for platelet lysis. (1990) (26)
Poor Relationship between Phenotypes of Protein S Deficiency and Mutations in the Protein S Alpha Gene (1999) (26)
The Effect of Instrumentation on Thromboplastin Calibration (1992) (26)
Nomenclature of Quantities and Units in Thrombosis and Haemostasis (Recommendation 1993) (1994) (26)
Oral Contraceptives Are a Risk Factor for Cerebral Vein Thrombosis (1996) (26)
Common variants in the haemostatic gene pathway contribute to risk of early-onset myocardial infarction in the Italian population (2011) (26)
Mutations in hemophilia Bm occur at the Arg180-Val activation site or in the catalytic domain of factor IX. (1990) (26)
Immune status of human immunodeficiency virus seropositive and seronegative hemophiliacs infused for 3.5 years with recombinant factor VIII. The Kogenate Study Group. (1994) (25)
Glanzmann thrombasthenia and Bernard-Soulier syndrome in south Iran. (2005) (25)
Calibration of Local Systems with Lyophilized Calibrant Plasmas Improves the Interlaboratory Variability of the INR in the Italian External Quality Assessment Scheme (1999) (25)
In Vivo Thrombin Generation and Activity During and After Intravenous Infusion of Heparin or Recombinant Hirudin in Patients With Unstable Angina Pectoris (2000) (25)
Factor V (Arg 506-->Gln) mutation in young survivors of myocardial infarction. (1996) (25)
Point-of-care coagulation monitors calibrated for the international normalized ratio for cirrhosis (INRliver) can help to implement the INRliver for the calculation of the MELD score. (2009) (25)
Enhancement of plasminogen activator by vasopressin and adrenaline: a role of cyclic AMP? (1974) (25)
New therapies for von Willebrand disease. (2019) (25)
The significance of protein C antigen in acute and chronic liver biliary disease. (1985) (25)
The In Vitro Production of Thromboxane B2 by Platelets of Diabetic Patients Is Normal at Physiological Concentrations of lonized Calcium (1993) (25)
Laboratory screening of thrombophilia. Evaluation of the diagnostic efficacy of a global test to detect congenital deficiencies of the protein C anticoagulant pathway (1998) (25)
Thrombophilic Mutations in Iran (2000) (24)
Gender difference in drug use in hospitalized elderly patients. (2015) (24)
The Outbreak of Hepatitis A in Italian Patients with Hemophilia: Facts and Fancies (1994) (24)
A Mutation in the Protein S Pseudogene Is Linked to Protein S Deficiency in a Thrombophilic Family (1989) (24)
Effect on blood coagulation of massive intravascular haemolysis. (1968) (24)
A randomized, placebo-controlled, blind anti-AIDS clinical trial : safety and immunogenicity of a specific anti-IFNα immunization (1994) (24)
An increased factor VIII antigen as an indicator of endothelial damage in measles. (1979) (24)
Reduced Effect of Exercise and DDAVP on Factor VIII-von Willebrand Factor and Plasminogen Activator after Sequential Application of Both the Stimuli (1984) (24)
Adherence to antibiotic treatment guidelines and outcomes in the hospitalized elderly with different types of pneumonia. (2015) (24)
Changes of Prothrombin Fragment 1+2 (F 1+2) as a Function of Increasing Intensity of Oral Anticoagulation (1998) (24)
von Willebrand factor collagen binding assay in von Willebrand disease type 2A, 2B, and 2M (2006) (24)
The natural history of hepatitis C virus infection in Italian patients with von Willebrand's disease: a cohort study. (2006) (24)
Present and future challanges in the treatment of haemophilia: a clinician's perspective. (2013) (24)
High efficacy of combined therapy with pegylated interferon plus ribavirin in patients with hemophilia and chronic hepatitis C. (2006) (24)
Prescription drug use among older adults in Italy: a country-wide perspective. (2014) (24)
A Natural Prothrombin Mutant Reveals an Unexpected Influence of A-chain Structure on the Activity of Human α-Thrombin* (2004) (24)
Platelet reactive conformation and multimeric pattern of von Willebrand factor in acquired thrombotic thrombocytopenic purpura during acute disease and remission (2011) (23)
Porcine recombinant factor VIII: an additional weapon to handle anti-factor VIII antibodies. (2017) (23)
The Health and Economic Burden of Air Pollution. (2015) (23)
Abnormal Protac-induced coagulation inhibition chromogenic assay results are associated with an increased risk of recurrent venous thromboembolism (2010) (23)
Comparison of Health Care Resource Utilization by Immigrants Versus Native Elderly People (2016) (23)
Mechanistic studies on ADAMTS13 catalysis. (2008) (23)
Results of a Multicenter Study Assessing the Status of Standardization of a Recombinant Thromboplastin for the Control of Oral Anticoagulant Therapy (1994) (23)
Red cells playing as activated platelets in thalassemia intermedia (2010) (23)
PLASMA LEVELS OF THE VON WILLEBRAND FACTOR-CLEAVING PROTEASE IN PHYSIOLOGICAL AND PATHOLOGICAL CONDITIONS IN CHILDREN (2002) (23)
Transmission of hepatitis G virus in patients with angioedema treated with steam‐heated plasma concentrates of C1 inhibitor (1998) (23)
Pharmacokinetic properties of IB1001, an investigational recombinant factor IX, in patients with haemophilia B: repeat pharmacokinetic evaluation and sialylation analysis (2012) (23)
Severe factor V deficiency: exon skipping in the factor V gene causing a partial deletion of the C1 domain (2003) (23)
Role for platelet von willebrand factor in supporting platelet‐vessel wall interactions in von willebrand disease (1989) (23)
Management of Bleeding Associated with New Oral Anticoagulants (2015) (23)
Proteolysis of von Willebrand factor after thrombolytic therapy in patients with acute myocardial infarction (1992) (23)
In vitro and ex vivo effects of indobufen on human platelet aggregation, the release reaction and thromboxane B2 production. (1987) (23)
Familial aggregation of early-onset myocardial infarction. (2010) (22)
Multimeric pattern of plasma and platelet von willebrand factor is normal in uremic patients (1993) (22)
Adhesive properties of the carbohydrate-modified von Willebrand factor (CHO-vWF). (1988) (22)
Hemophilia in the 1990s: principles of management and improved access to care. (1992) (22)
Progress in the contemporary management of hemophilia: The new issue of patient aging. (2017) (22)
Allele Frequency of CYP2C9 Gene Polymorphisms in Iran (2002) (22)
Development of factor VIII antibody in haemophilic monozygotic twins. European Study Group of Factor VIII Antibody. (2009) (22)
How to evaluate the influence of blood collection systems on the international sensitivity index. Protocol applied to two new evacuated tubes and eight coagulometer/thromboplastin combinations. (2002) (22)
Hemostatic alterations are unrelated to the stage of tumor in untreated malignant melanoma and breast carcinoma. (1985) (22)
Potentially Inappropriate Medications, Drug–Drug Interactions, and Anticholinergic Burden in Elderly Hospitalized Patients: Does an Association Exist with Post-Discharge Health Outcomes? (2020) (22)
Missense or splicing mutation? The case of a fibrinogen Bbeta-chain mutation causing severe hypofibrinogenemia. (2004) (22)
Prediction of factor VIII inhibitor development in the SIPPET cohort by mutational analysis and factor VIII antigen measurement (2018) (22)
Fibrotic interstitial lung diseases and air pollution: a systematic literature review (2020) (22)
Activated partial thromboplastin time (APTT). New indications for an old test? (2006) (21)
Thrombotic thrombocytopenic purpura and the hemolytic uremic syndrome: much progress and many remaining issues. (2007) (21)
Afibrinogenemia: first identification of a splicing mutation in the fibrinogen gamma chain gene leading to a major gamma chain truncation (2000) (21)
Prevalence, characteristics and treatment of chronic pain in elderly patients hospitalized in internal medicine wards. (2018) (21)
Detection of circulating released platelets after renal transplantation. (1982) (21)
Poor Comparability of Prothrombin Fragment 1 + 2 Values Measured by Two Commercial ELISA Methods: Influence of Different Anticoagulants and Standards (1994) (21)
Immunological Heterogeneity of Haemophilia B: a Multicentre Study of 98 Kindreds (1978) (21)
Prophylaxis of venous thromboembolism in elderly patients with multimorbidity (2013) (21)
Sex-Differences in the Pattern of Comorbidities, Functional Independence, and Mortality in Elderly Inpatients: Evidence from the RePoSI Register (2019) (21)
Emergency department visits in older people: pattern of use, contributing factors, geographical differences and outcomes (2017) (21)
Management of antithrombotic therapy for acute coronary syndromes and atrial fibrillation in patients with hemophilia (2012) (21)
The never ending success story of tranexamic acid in acquired bleeding (2020) (21)
State of Care for Hemophilia in Pediatric Patients (2002) (21)
Apolipoprotein(a) Kringle-IV Type 2 Copy Number Variation Is Associated with Venous Thromboembolism (2016) (21)
A survey of inherited thrombotic syndromes in italy (1989) (21)
Appropriateness of oral anticoagulant therapy prescription and its associated factors in hospitalized older people with atrial fibrillation (2018) (21)
Ticlopidine Facilitates the Deaggregation of Human Platelets Aggregated by Thrombin (1994) (20)
Comparative evaluation of the pharmacokinetics of three monoclonal factor VIII concentrates. (1991) (20)
Accelerated schedule of hepatitis B vaccination in patients with hemophilia (1993) (20)
Telemedicine and telerehabilitation: current and forthcoming applications in haemophilia. (2019) (20)
Erratum: The hemophilias - From royal genes to gene therapy (New England Journal of Medicine (June 7, 2001) 344 (1773-9)) (2001) (20)
Thromboembolism Following Prothrombin Complex Concentrates and Major Surgery in Severe Liver Disease (1978) (20)
Results of a collaborative study for fibrinogen measurement. Evidence that the use of a common calibrator improves interlaboratory agreement (1994) (20)
Antithrombin III Milano 2: a single base substitution in the thrombin binding domain detected with PCR and direct genomic sequencing. (1989) (20)
Ways to reduce the risk of transmission of viral infections by plasma and plasma products. A comparison of methods, their advantages and disadvantages. (1988) (20)
Role of synovectomy in hemophilic arthropathy. (1977) (20)
Imatinib and polypharmacy in very old patients with chronic myeloid leukemia: effects on response rate, toxicity and outcome (2016) (20)
Effect of Des-Amino-D-Arginine Vasopressin (DDAVP) on Plasma Levels of Platelet and Endothelial Cell Release Products (1983) (20)
Disability, and not diabetes, is a strong predictor of mortality in oldest old patients hospitalized with pneumonia. (2018) (19)
CONCENTRATES OF CLOTTING-FACTOR IX (1976) (19)
Premature termination codon mutations in the von Willebrand factor gene are associated with allele-specific and position-dependent mRNA decay (2010) (19)
Desmopressin: an historical introduction (2007) (19)
Inflammatory and prothrombotic parameters in normotensive non-diabetic obese women: effect of weight loss obtained by gastric banding (2012) (19)
Adjunct agents for bleeding (2014) (19)
Thromboembolic incidence with transiently elevated levels of coagulation factors in patients with von Willebrand disease treated with VWF:FVIII concentrate during surgery (2014) (19)
Multicenter Evaluation of Three Commercial Methods for Measuring Protein S Antigen (1992) (19)
Non‐thrombotic‐, non‐inhibitor‐associated adverse reactions to coagulation factor concentrates for treatment of patients with hemophilia and von Willebrand’s disease: a systematic review of prospective studies (2012) (19)
Multiple dental extractions with a new prothrombin complex concentrate in two patients with factor VIII inhibitors. (1979) (19)
The elusive pathogenesis of von Willebrand disease Vicenza. (2002) (19)
The European Haemophilia Network (EUHANET). (2014) (19)
Fc-fusion technology and recombinant FVIII and FIX in the management of the hemophilias (2014) (19)
Desmopressin: a nontransfusional treatment of hemophilia and von Willebrand disease. (1992) (19)
Decrease and rapid recovery of protein C after plasma exchange (1986) (19)
Analysis of Arg834Gln and Val902Glu type 2A von Willebrand disease mutations: studies with recombinant von Willebrand factor and correlation with patient characteristics. (1996) (19)
Tailoring hemostatic therapies to lower inhibitor development in previously untreated patients with severe hemophilia A (2016) (19)
More on: high thrombin generation and the risk of recurrent venous thromboembolism (2009) (19)
Determinants of plasma factor VIIa levels in humans. (1995) (19)
A Simplified Procedure for Thromboplastin Calibration -The Usefulness of Lyophilized Plasmas Assessed in a Collaborative Study (1996) (18)
Type II H von willebrand disease: New structural abnormality of plasma and platelet von willebrand factor in a patient with prolonged bleeding time and borderline levels of ristocetin cofactor activity (1989) (18)
INDOBUFEN VERSUS ASPIRIN PLUS DIPYRIDAMOLE AFTER CORONARY-ARTERY BYPASS-SURGERY (1991) (18)
Direct Proof of Extreme Lyonization as a Cause of Low Factor VIII Levels in Females (1978) (18)
Warfarin and acenocoumarol dose requirements according to CYP2C9 genotyping in North‐Italian patients (2003) (18)
Markers of procoagulant imbalance in patients with localized melanomas and autoimmune disorders (1993) (18)
Prognostic value of estimated glomerular filtration rate in hospitalized elderly patients (2014) (18)
Studies on hemophilia A in Sardinia bearing on the problems of multiple allelism, carrier detection, and differential mutation rate in the two sexes. (1984) (18)
Human Platelet Aggregation and Release Reaction Induced by Platelet Activating Factor (PAF-Acether) – Effects of Acetylsalicylic Acid and External Ionized Calcium (1985) (18)
Kreuth V initiative: European consensus proposals for treatment of hemophilia using standard products, extended half-life coagulation factor concentrates and non-replacement therapies (2020) (18)
Molecular Mapping of the Chloride-binding Site in von Willebrand Factor (VWF) (2006) (18)
Active platelet‐binding conformation of plasma von Willebrand factor in young women with acute myocardial infarction (2010) (18)
A Small Animal Model for Electrocardiographic Abnormalities Observed After An Experimental Subarachnoid Hemorrhage (18)
Specificity of hepatitis C antibody ELISA in patients with haemophilia (1990) (18)
Inherited factors in thrombosis. (1988) (18)
Kreuth IV: European consensus proposals for treatment of haemophilia with coagulation factor concentrates (2017) (18)
High Prevalence of Serum Cryoglobulins in Multitransfused Hemophilic Patients With Chronic Hepatitis C (1998) (18)
Determination of pharmacokinetics of replacement factor VIII. (1990) (18)
Increased Fibrinopeptide A after Prothrombin Complex Concentrates (1980) (18)
Improving primary care in Europe beyond COVID-19: from telemedicine to organizational reforms (2020) (18)
Under the auspices of the Italian Association for the Study of Liver Diseases (AISF) and the Italian Society of Internal Medicine (SIMI) (2016) (17)
Miracle of haemophilia drugs: Personal views about a few main players (2018) (17)
Antibodies to factor VIII-von Willebrand factor in congenital and acquired von Willebrand's disease. (1984) (17)
Haemophilia B is clinically less severe than haemophilia A: further evidence. (2018) (17)
Progression to AIDS among Italian HIV‐seropositive haemophiliacs (1991) (17)
Secondary Long-Term Prophylaxis in Severe Patients with von Willebrand’s Disease: An Italian Cohort Study. (2005) (17)
Modifiers of clinical phenotype in severe congenital hemophilia. (2017) (17)
Implementation of the Frailty Index in hospitalized older patients: Results from the REPOSI register. (2018) (17)
α1-antitrypsin therapy in a case of thrombotic thrombocytopenic purpura (1995) (17)
Quality assurance program for whole blood prothrombin time-international normalized ratio point-of-care monitors used for patient self-testing to control oral anticoagulation. (2004) (17)
Oral anticoagulant use in octogenarian European patients with atrial fibrillation: A subanalysis of PREFER in AF. (2017) (17)
[Hemostasis and liver disease]. (1981) (17)
Uncertain times for research on hemophilia and allied disorders (2005) (17)
Effect of Abciximab on Prothrombin Activation and Thrombin Generation in Acute Coronary Syndromes Without ST-Segment Elevation: Global Utilization of Strategies to Open Occluded Coronary Arteries Trial IV in Acute Coronary Syndromes (GUSTO IV ACS) Italian Hematologic Substudy (2002) (17)
Cholesterol-adjusted vitamin E serum levels are associated with cardiovascular events in patients with non-valvular atrial fibrillation. (2013) (17)
Gly319 → Arg substitution in the dysfunctional prothrombin Segovia (1999) (17)
Functional Assays of Protein C: Comparison of Two Snake-Venom Assays with Two Thrombin Assays (1988) (17)
The hemostatic balance revisited through the lessons of mankind evolution (2008) (17)
Air pollution levels and cardiovascular health: Low is not enough (2017) (17)
A multicenter controlled, randomized, open trial of interferon alpha2b treatment of anti-human immunodeficiency virus-negative hemophilic patients with chronic hepatitis C. Hepatitis Study Group of the Association of Italian Hemophilia Centers. (1997) (17)
Embryo implantation after assisted reproductive procedures and maternal thrombophilia (2003) (16)
Primary hyperfibrinolysis: Facts and fancies. (2018) (16)
Prognostic value of degree and types of anaemia on clinical outcomes for hospitalised older patients. (2017) (16)
Management of von Willebrand disease in developing countries. (2005) (16)
Homozygous 2bp Deletion in the Human Factor VII Gene: A Non-Lethal Mutation that Is Associated with a Complete Absence of Circulating Factor VII (2000) (16)
Resistance to activated protein C mimicking dysfunctional protein C: diagnostic approach (1996) (16)
Ageing successfully with haemophilia: A multidisciplinary programme (2018) (16)
Protein S mRNA in Patients with Protein S Deficiency (1995) (16)
VON WILLEBRAND FACTOR ABNORMALITIES IN TWO PATIENTS WITH URAEMIA (1988) (16)
Frequency of Factor V Arg506 Gin in Italians (1996) (16)
Novel investigations on the protective role of the FVIII/VWF complex in inhibitor development (2014) (16)
Treatment of haemophilia: building on strength in the third millennium (2011) (16)
Platelet functions after intravenous administration in man of cyclic-AMP and related drugs (1974) (16)
Heated clotting factors and seroconversion for human immunodeficiency virus in three hemophilic patients. (1987) (16)
Multicenter evaluation of a new chromogenic factor X assay in plasma of patients on oral anticoagulants. (1980) (16)
Oxidized von Willebrand factor is efficiently cleaved by serine proteases from primary granules of leukocytes: divergence from ADAMTS‐13 (2011) (16)
Alloantibodies in von Willebrand Disease (2017) (16)
Role of the 2 adenine (g.11293_11294insAA) insertion polymorphism in the 3′ untranslated region of the factor VII (FVII) gene: molecular characterization of a patient with severe FVII deficiency (2005) (16)
A contemporary look at FVIII inhibitor development: still a great influence on the evolution of hemophilia therapies (2018) (16)
Electroblot and Immunoperoxidase Staining for Rapid Screening of the Abnormalities of the Multimeric Structure of von Willebrand Factor in von Willebrand’s Disease (1986) (16)
Comorbidity does not mean clinical complexity: evidence from the RePoSI register (2019) (15)
Association of a single nucleotide polymorphism of the NPR3 gene promoter with early onset ischemic stroke in an Italian cohort. (2013) (15)
Management of orthopaedic surgery in rare bleeding disorders (2014) (15)
Genetic characterization of patients with Bernard-Soulier syndrome and their relatives from Southern Iran (2007) (15)
Does enhancement of oxidative stress markers mediate health effects of ambient air particles? (2014) (15)
Prognostic value of hemostatic parameters after liver transplantation. (1992) (15)
Treatment of hemophilia: recombinant factors only? No (2003) (15)
Phenotypic and genetic analysis of a compound heterozygote for dys‐ and hypoprothrombinaemia (2003) (15)
Virology of the Hepatitis A Epidemic in Italy (1994) (15)
Diagnosis and management of acquired von Willebrand syndrome. (2003) (15)
Appropriateness of antiplatelet therapy for primary and secondary cardio‐ and cerebrovascular prevention in acutely hospitalized older people (2017) (15)
Coinheritance of the HR 2 Haplotype in the Factor V Gene Confers an Increased Risk of Venous Thromboembolism to Carriers of Factor V R 506 Q ( Factor V Leiden ) (1999) (15)
Drug-drug interactions involving CYP3A4 and p-glycoprotein in hospitalized elderly patients. (2019) (15)
Factor VIII activity as measured by an amidolytic assay compared with a one-stage clotting assay. (1986) (15)
Standardization of the APC Resistance Test. Effects of Normalization of Results by Means of Pooled Normal Plasma (1998) (15)
Advantages and limits of ADAMTS13 testing in the prognostic assessment of thrombotic thrombocytopenic purpura. (2012) (15)
Desmopressin‐induced thrombocytopenia in type i platelet discordant von willebrand disease (1993) (15)
Heterogeneity in type IIB von Willebrand disease: Two unrelated cases with no family history and mild abnormalities of ristocetin‐induced interaction between von willebrand factor and platelets (1986) (15)
Bleeding symptoms in patients diagnosed as type 3 von Willebrand disease: Results from 3WINTERS‐IPS, an international and collaborative cross‐sectional study (2020) (15)
Pain and Frailty in Hospitalized Older Adults (2020) (15)
Pain and Frailty in Hospitalized Older Adults (2020) (15)
Isolation of an abnormal protein C molecule from the plasma of a patient with thrombotic diathesis. (1988) (15)
High Fibrinopeptide A (FPA) Levels in Acute Non-Lymphocytic Leukemia Are Reduced by Heparin Administration (1984) (15)
Intracranial bleeding in haemophilia: a study of eleven cases. (1982) (14)
The International Society for Thrombosis and Haemostasis owns its official journal: the future has begun! (2003) (14)
Laboratory monitoring of replacement therapy for major surgery in von Willebrand disease (2017) (14)
Effects of Factor VIII Concentrates on the Immune System of Patients with Hemophilia (1995) (14)
Investigational drugs for coagulation disorders (2013) (14)
Clinical evaluation of a fully automated chromogenic method for prothrombin time compared with a conventional coagulation method. (1984) (14)
Laboratory Diagnosis of Lupus Anticoagulants (2002) (14)
Familial Overexpression of β Antithrombin Caused by an Asn135Thr Substitution (1999) (14)
Fibrin clot structure is affected by levels of particulate air pollution exposure in patients with venous thrombosis. (2016) (14)
Thromboprophylaxis in the oldest old with atrial fibrillation: between Scylla and Charybdis. (2013) (14)
PROTEIN C CONCENTRATES FOR THERAPEUTIC USE (1983) (14)
Prevalence of type 2b ‘Malmö/New York’ von Willebrand disease in Italy: the role of von Willebrand factor gene conversion (2008) (14)
Use of prophylaxis to prevent complications of hemophilia. (2001) (14)
Systemic clotting activation by low-grade endotoxaemia in liver cirrhosis: a potential role for endothelial procoagulant activation. (1997) (14)
Serum hepatitis B virus DNA detects cryptic hepatitis B virus infections in multitransfused hemophilic patients (1990) (14)
Comorbidities in persons with haemophilia aged 60 years or more compared with age‐matched people from the general population (2018) (14)
Monoclonal Antibodies Directed to the Calcium-Free Conformation of Human Protein S (1989) (14)
The real value of thrombophilia markers in identifying patients at high risk of venous thromboembolism (2014) (14)
von Willebrand disease in the 21st century: current approaches and new challenges (2009) (14)
Benefits and limitations of extended plasma half-life factor VIII products in hemophilia A (2020) (14)
Acquired storage pool disease in platelets during disseminated intravascular coagulation (1976) (14)
High Levels of Tissue Factor Pathway Inhibitor in Patients with Nephrotic Proteinuria (1999) (14)
Joint use of cardio-embolic and bleeding risk scores in elderly patients with atrial fibrillation. (2013) (14)
Familial Overexpression of β Antithrombin Caused by an Asn135Thr Substitution (1999) (14)
Integrated postural analysis in children with haemophilia (2014) (13)
Risk factors for three-month mortality after discharge in a cohort of non-oncologic hospitalized elderly patients: Results from the REPOSI study. (2018) (13)
Pattern of in‐hospital changes in drug use in the older people from 2010 to 2016 (2017) (13)
Pattern of comorbidities and 1-year mortality in elderly patients with COPD hospitalized in internal medicine wards: data from the RePoSI Registry (2020) (13)
Pattern of comorbidities and 1-year mortality in elderly patients with COPD hospitalized in internal medicine wards: data from the RePoSI Registry (2020) (13)
Recurrent Late Fetal Death in Women with and without Thrombophilia (2002) (13)
Low risk of transmission of the human immunodeficiency virus by a solvent‐detergent‐treated commercial factor VIII concentrate (1992) (13)
Phenotype commitment in vascular smooth muscle cells derived from coronary atherosclerotic plaques: differential gene expression of endothelial nitric oxide synthase. (2009) (13)
Liver transplantation in severe von Willebrand disease (1991) (13)
New drugs for thromboprophylaxis in atrial fibrillation. (2012) (13)
Living alone as an independent predictor of prolonged length of hospital stay and non-home discharge in older patients. (2018) (13)
Familial dysfunctional protein C. (1986) (13)
Relationship between atrial fibrillation and cognitive decline in individuals aged 80 and older. (2017) (13)
Prophylaxis for adults with haemophilia: towards a personalised approach? (2012) (13)
Pharmacogenetic aspects of the use of oral contraceptives and the risk of thrombosis. (2003) (13)
Anti-alpha interferon immunization: safety and immunogenicity in asymptomatic HIV positive patients at high risk of disease progression. (1995) (13)
Need for randomized trials in hemophilia (2006) (13)
Noise and air pollution as triggers of hypertension. (2021) (13)
Heightened proteolysis of the von Willebrand factor subunit in patients with von Willebrand disease hemizygous or homozygous for the C2362F mutation (2000) (13)
Type 2A (IIH) von Willebrand disease is due to mutations that affect von Willebrand factor multimerization (2009) (13)
Markers of hypercoagulability in cancer patients. (1997) (13)
Progress in fibrinolysis (1975) (13)
Platelet/von Willebrand factor inhibitors to the rescue of ischemic stroke. (2010) (13)
Thalassemia trait and arterial thromboembolic events: a systematic review and a meta‐analysis of the literature (2011) (13)
Continuous infusion of porcine factor VIII in patients with haemophilia A and high‐responding inhibitors: stability and clinical experience (2001) (13)
Cellogel electrophoresis of haemoglobins. (1968) (13)
A new variant of von Willebrand disease (type II I) with a normal degree of proteolytic cleavage of von Willebrand factor. (1992) (13)
Identification of Four Novel Polymorphisms in the Aα and γ Fibrinogen Genes and Analysis of Association with Plasma Levels of the Protein (2001) (13)
Treatment of Von Willebrand Disease (2001) (13)
Summary report of the First International Conference on inhibitors in haemophilia A. (2017) (13)
Repeated Release of the Tissue Factor Pathway Inhibitor (1994) (13)
Changes in fibrinolysis in patients with localized tumors. (1990) (13)
Understanding organ dysfunction in thrombotic thrombocytopenic purpura (2015) (13)
Secondary long-term prophylaxis in von Willebrand disease: an Italian cohort study (2009) (12)
Charge heterogeneity of human protein C revealed by isoelectric focusing in immobilized pH gradients (1985) (12)
Inhibitors of factor VIII in hemophilia. (2009) (12)
Letter: Enhanced factor VIII activity in von Willebrand's disease. (1974) (12)
Identification of three candidate mutations causing type IIA von Willebrand disease using a rapid, nonradioactive, allele-specific hybridization method (1993) (12)
The stigma of low opioid prescription in the hospitalized multimorbid elderly in Italy (2015) (12)
Biochemical characterization of a recombinant von Willebrand factor (VWF) with combined type 2B and type 1 defects in the VWF gene in two patients with a type 2A phenotype of von Willebrand disease (2007) (12)
Desmopressin in Bleeding Disorders (1993) (12)
Hepatitis C virus/human immunodeficiency virus coinfection in hemophiliacs: high rates of sustained virologic response to pegylated interferon and ribavirin therapy (2009) (12)
Haemophilia treatment protocols around the world: towards a consensus (1998) (12)
Alloantibodies in congenital von Willebrand’s disease (1991) (12)
Comparative analysis of the pivotal studies of extended half‐life recombinant FVIII products for treatment of haemophilia A (2021) (12)
Mechanisms of Disease The Coagulopathy of Chronic Liver Disease (2011) (12)
What is the importance of the 'small pool concept' in the preparation of fraciton I and cryoprecipitates for the prevention of post-transfusion hepatitis? (1980) (12)
The Use of Plasma‐Derived Concentrates (2011) (12)
Comparison of a functional assay for protein C with two immunoassays. (1985) (11)
Acquired Storage Pool Disease in Myeloproliferative Disorders (1979) (11)
Fine particulate: it matters (2010) (11)
Choice and Outcomes of Rate Control versus Rhythm Control in Elderly Patients with Atrial Fibrillation: A Report from the REPOSI Study (2018) (11)
Clinical and laboratory patterns of the haemolytic uraemic syndrome and thrombotic thrombocytopenic purpura in southern Iran (2006) (11)
PRELIMINARY TRIAL OF CYCLOPHOSPHAMIDE IN THE MANAGEMENT OF HEMOPHILIACS WITH FACTOR VIII INHIBITORS * (1975) (11)
Effect on Platelet Functions of Derivatives of Cyclic Nucleotides (1978) (11)
Abnormalities of lymphocyte subsets are correlated with concentrate consumption in asymptomatic Italian hemophiliacs treated with concentrates made from American plasma (1984) (11)
Determinants of plasma factor VIIa levels in humans (1995) (11)
Recommended Protocol for the Study of the Ex Vivo Biological Effects of Virus-Inactivated Plasma Concentrates in Patients with von Willebrand Disease (1992) (11)
INCREASED PROTEIN C AND FIBRINOPEPTIDE A CONCENTRATION IN PATIENTS WITH ANGINA (1988) (11)
Conditions Influencing the Interaction of Asialo von Willebrand Factor with Human Platelets – The Effects of External Ionized Calcium Concentration and the Role of Arachidonate Pathway (1988) (11)
Vasopressin Analogues (1987) (11)
Effect of CIBA 13,437-Su on serum cholesterol and triglycerides, plasma fibrinogen, fibrinolysis and platelet adhesiveness in patient with ischemic hert disease. (1971) (11)
Haematology clinic: Haemophilia A (2014) (11)
Evolution of the European guidelines for the clinical development of factor VIII products: little progress towards improved patient management (2013) (11)
Urokinase : basic and clinical aspects (1982) (11)
Addressing current challenges in haemophilia care: consensus recommendations of a European Interdisciplinary Working Group (2005) (11)
Circulating endothelial cells (CECs) and progenitors (CEPs) in severe haemophiliacs with different clinical phenotype (2009) (11)
Expression of endothelial protein C receptor and thrombomodulin in human coronary atherosclerotic plaques. (2004) (11)
Pediatric requirements in Europe stymie help for hemophilia (2014) (10)
Dosing anticoagulant therapy with coumarin drugs: is genotyping clinically useful? No (2008) (10)
Incidence and Determinants of Bleeding in Different Types of von Willebrand Disease: Results of the First Prospective Multicenter Study on 814 Italian Patients. (2007) (10)
Patterns of changes of anti‐ADAMTS13 after plasma exchange (2006) (10)
Prevalence of Mutant Factor V in Italian Patients with Hereditary Deficiencies of Antithrombin, Protein C or Protein S (1996) (10)
Inappropriate prescription of benzodiazepines in acutely hospitalized older patients (2019) (10)
Tailoring care to haemophilia patients' needs: which specialty and when? (2015) (10)
Fibrinolysis in cholestatic jaundice. (1973) (10)
Consistency of ADAMTS‐13 activity assays: a moderately optimistic view (2003) (10)
The safety of pharmacologic options for the treatment of persons with hemophilia (2016) (10)
Content and release of beta-thromboglobulin and platelet factor 4 in patients with qualitative platelet defects. (1979) (10)
Biochemical characteristics of therapeutic plasma concentrates used in the treatment of von Willebrand disease. (1994) (10)
A critical role for Gly25 in the B chain of human thrombin (2005) (10)
Effect of abciximab on prothrombin activation and thrombin generation in patients with acute myocardial infarction also receiving reteplase. (2004) (10)
Long‐term follow‐up of randomized trials of immediate versus deferred zidovudine in symptom‐free HIV infection (1998) (10)
Particulate matter phagocytosis induces tissue factor in differentiating macrophages (2016) (10)
International sensitivity index calibration of the near-patient testing prothrombin time monitor, ProTime. (2003) (10)
The Genetic Defect of Type I von Willebrand Disease “Vicenza” Is Linked to the von Willebrand Factor Gene (1993) (10)
Combined Use of DNA Probes in First-Trimester Prenatal Diagnosis of Hemophilia A (1987) (9)
Lack of Correlation Between Activation of Hemostatic Mechanism and Inflammation in Unstable Angina Pectoris (1998) (9)
Von Willebrand's Disease. (2017) (9)
A Pilot Study of Pro-Urokinase in the Treatment of Deep Vein Thrombosis (1994) (9)
Studies of multimerin in patients with von Willebrand disease and platelet von Willebrand factor deficiency (1998) (9)
Venous thromboembolism and hormone replacement therapy. (2001) (9)
Methods for the preparation of washed platelet suspensions. (1972) (9)
Blood lead levels following consumption of game meat in Italy (2017) (9)
Mechanism of hemostasis defects and management of bleeding in patients with acute coronary syndromes. (2010) (9)
Desmopressin (DDAVP) and factor VIII: the tale as viewed from Milan (and Malmö) (2003) (9)
Anti-LAV and Concentrate Consumption in Italian Hemophiliacs (1985) (9)
Identification of four novel polymorphisms in the Aalpha and gamma fibrinogen genes and analysis of association with plasma levels of the protein. (2001) (9)
Von Willebrand disease type 2N: An update (2021) (9)
Choice of replacement therapy for hemophilia: recombinant products only? (2000) (9)
Standardization of activated protein C resistance testing: effect of residual platelets in frozen plasmas assessed by commercial and home‐made methods (2003) (9)
Airborne pollution and cardiovascular disease: burden and causes of an epidemic. (2013) (9)
Effects of subcutaneously administered dermatan sulfate (MF 701) on the coagulation and fibrinolytic parameters of healthy volunteers. (1991) (9)
Viral safety of coagulation factor concentrates. (1993) (9)
Thrombophilia screening: little role for the JAK2V617F mutation. (2008) (9)
Effect of Oral Aspirin on Plasma Levels of Vitamin K-Dependent Clotting Factors – Studies in Healthy Volunteers (1988) (9)
Serum hepatitis B virus DNA detects cryptic hepatitis B virus infections in multitransfused hemophilic patients. (1990) (8)
Pro-coagulant imbalance in patients with chronic liver disease. (2010) (8)
Side effects of antihemophilic concentrates. (2009) (8)
Dabigatran versus warfarin in patients with atrial fibrillation. (2009) (8)
Aging with Hemophilia: The Challenge of Appropriate Drug Prescription (2019) (8)
Psychological impact of thrombosis in the young (2006) (8)
High-titre inhibitors in previously untreated patients with severe haemophilia A receiving recombinant or plasma-derived factor VIII: a budget-impact analysis. (2018) (8)
Impact of the post‐COVID‐19 condition on health care after the first disease wave in Lombardy (2022) (8)
Polymorphisms in the factor VII gene and the risk of myocardial infarction. (2001) (8)
Prevalence of HTLV‐IIVLAV antibodies in Italian asymptomatic hemophiliacs given commercial concentrates of factors VIII and IX (1986) (8)
B19 Parvovirus Withstands “Super Heating” in Antihemophilic Concentrates (1996) (8)
Autoimmune hemophilia at rescue (2009) (8)
Predictors of clinical events occurring during hospital stay among elderly patients admitted to medical wards in Italy. (2016) (8)
The −308 G/A polymorphism in the tumor necrosis factor‐α gene is not associated with development and progression of rheumatoid arthritis in Argentinean patients (2016) (8)
Views of medical practitioners about deprescribing in older adults: Findings from an Italian qualitative study. (2020) (8)
Viral safety of plasma‐derived and recombinant products used in the management of haemophilia A and B (1995) (8)
Models for institutional and professional accreditation of haemophilia centres in Italy (2013) (8)
[HIV-related thrombocytopenias]. (2000) (8)
Prophylaxis in congenital coagulation disorders: past, present and future. (2008) (8)
The role of natural VWF/FVIII complex concentrates in contemporary haemophilia care: a guideline for the next decade (2012) (8)
Treatment with stanazolol of type I protein C deficiency in an Italian family (1984) (8)
Congenital deficiencies of anticoagulant proteins (antithrombin III and protein C). (1984) (8)
Multicentre comparison of nine coagulometers and manual tilt-tube methods for prothrombin time performance. (1983) (8)
Chromatographic and electrophoretic pattern of lactate and malate dehydrogenase in normal human adult and foetal muscle and in muscle of patients affected by Duchenne muscular dystrophy. (1966) (8)
More on: are randomized clinical trials the only truth? Not always (2006) (8)
Coagulation and platelet activation after retinal vein occlusions. (1982) (8)
Fifth Åland Island conference on von Willebrand disease (2018) (8)
Recombinant factor VIIa as haemostatic therapy in advanced liver disease. (2013) (7)
Antipsychotic prescription and mortality in hospitalized older persons (2017) (7)
Current status of non-transfusional haemostatic agents. (1999) (7)
Characterization of an Abnormal Antithrombin (Milano 2) with Defective Thrombin Binding (1986) (7)
Factor VII gene polymorphisms are not associated with myocardial infarction in young women (2005) (7)
Consumption of clotting factors in severe haemophilia patients undergoing prophylaxis and on‐demand treatment in Italy (2011) (7)
Immunogenicity of factor VIII concentrates in patients with hemophilia: a randomized clinical trial is warranted. (2007) (7)
The response of plasma von Willebrand factor to desmopressin (DDAVP) is related to the platelet levels of von Willebrand factor. (1992) (7)
Low risk of thrombosis in family members of patients with hyperhomocysteinaemia (2002) (7)
Hypercoagulability in congenital haemolytic anaemias. (2012) (7)
Risk of Venous Thromboembolism and Clinical Manifestations in Carriers of Antithrombin , Protein C , Protein S Deficiency , or Activated Protein C Resistance (1999) (7)
Post-authorization pharmacovigilance for hemophilia in Europe and the USA: Independence and transparency are keys. (2021) (7)
Hemostatic Functions in Hypoalpha and Hyperbetalipoproteinemias (1983) (7)
Hemophilia: State of the Art of Hematologic Care 1988 (1989) (7)
Assessing the risk of inhibitor formation with different factor VIII products. (2006) (7)
Effect of cyclic AMP and related drugs on plasminogen activator (1973) (7)
Aspects of the Clinical Management of Hereditary Thrombophilia: A Personal Perspective (2000) (7)
National survey of human immunodeficiency virus infection in Italian hemophiliacs: 1983–1987 (1988) (7)
Haemophilia in the 1990s: Report of a Joint Meeting of the World Health Organization and World Federation of Hemophilia (1991) (7)
Familial overexpression of beta antithrombin caused by an Asn135Thr substitution. (1999) (7)
Internal and geriatric medicine: an alliance for the challenges of the elderly. (2012) (7)
A novel two base pair deletion in the factor V gene associated with severe factor V deficiency. (2000) (7)
Thrombosis and bleeding disorders outside Western countries (2007) (7)
von Willebrand factor: what is its role in the immune response in haemophilia? (2011) (7)
Alpha(2)-macroglobulin levels are high in adult patients with congenital antithrombin deficiency. (2000) (7)
Oral and Poster Presentations (2003) (7)
The P303T mutation in the human factor VII (FVII) gene alters the conformational state of the enzyme and causes a severe functional deficiency (2004) (7)
Involvement of the IgE‐basophil system and mild complement activation in haemophilia B with anti‐factor IX neutralizing antibodies and anaphylaxis (2017) (7)
Viral safety of coagulation factor concentrates: memoirs from an insider (2018) (7)
Panel discussion on the treatment of patients with factor VIII inhibitors. (1984) (7)
Defensive medicine: Everything and its opposite. (2020) (7)
Electrophoretic characterization of glutamic oxalacetic transaminase in human red cells of different ages. (1966) (7)
Inherited deficiency of antithrombin III in an Italian kindred (1980) (7)
Sustainable and personalized nutrition: From earth health to public health. (2021) (7)
Pharmacist-driven medication recognition/ reconciliation in older medical patients. (2020) (7)
Simulation-based education for physicians to increase oral anticoagulants in hospitalized elderly patients with atrial fibrillation. (2019) (7)
In vivo experiments indicate that relatively high platelet deposition in von Willebrand's disease 'Vicenza' is caused by normal platelet-VWF levels rather than by high VWF-multimers in plasma. (1992) (6)
Elevation of thrombin-antithrombin complexes during thrombolytic therapy in patients with myocardial infarction (1990) (6)
Kaposi's sarcoma without human immunodeficiency virus antibody in a hemophiliac. (1986) (6)
Assessment of a new instrument (Coag-A-Mate X2) for performing global clotting tests and specific factor assays. (1985) (6)
Overview of Bleeding in Cancer Patients (2003) (6)
Coagulation and Blood Transfusion (1991) (6)
High-purity factor VIII concentrates produced without using monoclonal antibodies (1990) (6)
Predictive value of coagulation tests in arterial thrombosis (1988) (6)
The increased demand for plasma-derived factor VIII in Italy. (2017) (6)
Hyperprothrombinemia may result in scquired activated protein C reistance. (2000) (6)
Identification of three candidate mutations causing type IIA von Willebrand disease using a rapid, nonradioactive, allele-specific hybridization method. (1993) (6)
The demand for factor VIII and for factor IX and the toll fractionation product surplus management. (2013) (6)
Transfusion Requirements Are Correlated with the Degree of Proteolysis of von Willebrand Factor during Orthotopic Liver Transplantation (1997) (6)
Appropriateness of prescription of oral anticoagulant therapy in acutely hospitalized older people with atrial fibrillation. Secondary analysis of the SIM‐AF cluster randomized clinical trial (2019) (6)
Efficacy and safety of a recombinant factor VIII produced from a human cell line (simoctocog alfa) (2017) (6)
von Willebrand factor: a prima ballerina on two different stages. (2005) (6)
Plasma-derived medicinal products: demand and clinical use. (2013) (6)
CIRCULATING ANTICOAGULANTS IN HÆMOPHILIA (1970) (6)
Rate and appropriateness of polypharmacy in older patients with hemophilia compared with age‐matched controls (2018) (6)
More on: enhanced thrombin generation in patients with cirrhosis‐induced coagulopathy (2011) (6)
Clinical manifestations and complications of childbirth and replacement therapy in 385 Iranian patients with type 3 von Willebrand disease (2000) (6)
Need for Deprescribing in Hospital Elderly Patients Discharged with a Limited Life Expectancy: The REPOSI Study (2019) (6)
Sharing data of clinical trials. (2016) (6)
CLOTTING FACTORS IN VON WILLEBRAND'S DISEASE (1974) (6)
Von Willebrand's syndrome. (1979) (6)
Recommendations for factor VIII product source to treat patients with haemophilia A. (2017) (6)
Recombinant Human Von Willebrand Factor (rhVWF): First-In-Human Study Evaluating Pharmacokinetics, Demonstrating Safety and Tolerability In Type 3 Von Willebrand Disease (2010) (5)
Report on the workshop: Von Willebrand factor and thrombotic thrombocytopenic purpura (2001) (5)
Effect of prothrombin 19911 A>G polymorphism on the risk of cerebral sinus‐venous thrombosis (2010) (5)
Protective effect of prophylaxis on inhibitor development in children with haemophilia A: more convincing studies are required. Response to Calvez and Laurian (2006) (5)
Immunoradiometric Assay of Factor VIII Related Antigen (1975) (5)
Very Low Frequency of “Normandy Type” Mutations among Type 1 von Willebrand Disease Families (1995) (5)
Direct oral anticoagulants and cirrhosis: More evidence still needed for efficacy and safety in portal vein thrombosis. (2019) (5)
Incidence of low‐titre factor VIII inhibitors in patients with haemophilia A: meta‐analysis of observational studies (2017) (5)
A randomized, placebo-controlled, blind anti-AIDS clinical trial: safety and immunogenicity of a specific anti-IFN alpha immunization. (1994) (5)
Prophylactic management of patients with von Willebrand disease (2021) (5)
Clinical factors associated with death in 3044 COVID-19 patients managed in internal medicine wards in Italy: comment (2021) (5)
Coexistence of haemophilia A and von Willebrand's disease in the same kindred. (2009) (5)
Dissociated antibody responses to the s and pre‐s2 regions of the hepatitis b virus after vaccination in hemophiliacs (1989) (5)
Hemophilia [4] (multiple letters) (2001) (5)
Randomized double-blind, placebo-controlled trial of twice-daily zidovudine in asymptomatic haemophiliacs infected with the human immunodeficiency virus type 1. European-Australian Haemophilia Collaborative Study Group. (1994) (5)
Thromboxane generation by human monocytes enhances platelet function (1986) (5)
Multiple gene interaction and modulation of hemostatic balance (2009) (5)
Continuous infusion of porcine factor VIII: stability, microbiological safety and clinical experience (2002) (5)
The international normalized ratio to prioritize patients for liver transplantation: problems and possible solutions (2008) (5)
Changing epidemiology of the hemolytic uremic syndrome and thrombotic thrombocytopenic purpura in southern Iran (2006) (5)
Treatment of Hemophilia - More Amazing Progress. (2020) (5)
Characterization of a partial deletion of the factor VIII gene in a haemophiliac with inhibitor (1988) (5)
c.301C>T (p.Arg101Cys): A novel mutation in the thrombin-sensitive region of protein S associated with a dysfunctional protein (2006) (5)
Hospital Care of Older Patients With COPD: Adherence to International Guidelines for Use of Inhaled Bronchodilators and Corticosteroids. (2019) (5)
Erratum: Glazmann thrombasthenia and Bernard Soulier syndrome in South Iran (Clinical and Laboratory Haematology (2005) 27, (324-327)) (2006) (5)
Intelligent game engines for home exercises (exergames) in boys with haemophilia (2020) (5)
High levels of circulating von Willebrand factor inhibit the release of this protein but not of plasminogen activator after DDAVP. (1985) (5)
Supranormal antithrombin III levels induced by concentrate administration are ineffective in quenching thrombin generation in acute promyelocytic leukemia. (1993) (5)
Factor VIII inhibitors in previously treated hemophilic patients (2011) (5)
Carrier detection in factor VII congenital deficiency (1985) (5)
Traffic-related air pollution and the coronavirus pandemia: shadows and lights (2020) (5)
The importance of ABO blood group in pharmacokinetic studies in haemophilia A (2018) (5)
Abstract 4011: Influence Of Rs1333040, A Newly Discovered 9p21.3 Genetic Variant, On Clinical Outcomes In Early-onset Myocardial Infarction (2008) (5)
Management of Hemophilia in Older Patients (2017) (5)
Inhibitor development, immune tolerance and prophylaxis in haemophilia A – the need for an evidence‐based approach (2006) (5)
Hemorrhagic telangiectasia and hemophilia A: an occasional association? (1983) (4)
Thrombolytic therapy of acute deep vein thrombosis of the lower limbs: Choices, indications and limits (1984) (4)
Recombinant porcine factor VIII: a new instalment of a long story (2015) (4)
PCR analysis of HIV‐1 sequences and differential immunological features in seronegative and seropositive haemophiliacs (1992) (4)
Emerging drugs for hemophilia B (2014) (4)
Immunogenicity of a yeast‐recombinant hepatitis B vaccine in high‐risk children (1989) (4)
β-thromboglobulin and fibrinopeptide a in diabetes mellitus as markers of vascular damage (2007) (4)
Impact of Diabetes Mellitus and Its Comorbidities on Elderly Patients Hospitalized in Internal Medicine Wards: Data from the RePoSi Registry (2022) (4)
Vagaries of genetic association studies in myocardial infarction. (2003) (4)
A Randomized, Double-Blind, Placebo-Controlled, Clinical Outcome Study of ARC1779 In Patients with Thrombotic Thrombocytopenic Purpura (TTP) (2010) (4)
Treatment of von Willebrand disease (1998) (4)
Genome-Wide Association Studies in Myocardial Infarction and Coronary Artery Disease (2010) (4)
Initiation of Psycholeptic Medication During Hospitalization With Recommendation for Discontinuation After Discharge. (2020) (4)
CHARACTERISTICS OF LACTIC DEHYDROGENASES IN HUMAN ERYTHROCYTES. (1964) (4)
Thrombotic microangiopathies: the past as prologue. (2013) (4)
Chlorpropamide-alcohol flushing in non insulin-dependent diabetes: Prevalence of small and large vessel disease and of risk factors for angiopathy (1982) (4)
Therapeutic Duplicates in a Cohort of Hospitalized Elderly Patients: Results from the REPOSI Study (2016) (4)
Bleeding symptoms in heterozygous factor VIII deficiency (2010) (4)
Predictors of inhibitor eradication by primary immune tolerance induction in severe haemophilia A with high responding inhibitors (2021) (4)
Prognostic relevance of glomerular filtration rate estimation obtained through different equations in hospitalized elderly patients. (2018) (4)
Cardiovascular health and ambient air pollution: lower is not enough. (2020) (4)
Subunit Composition of Plasma von Willebrand Factor (vWF) in Two Uremic Patients with Acquired vWF Abnormalities (1992) (4)
Polypharmacy in older adults with severe haemophilia (2018) (4)
New anticoagulants in internal medicine: an update. (2010) (4)
Integrated care: easy in theory, harder in practice? (2021) (4)
Activation of the Protein C Pathway in Hereditary Thrombophilia (1998) (4)
Comparison between drug therapy-based comorbidity indices and the Charlson Comorbidity Index for the detection of severe multimorbidity in older subjects (2020) (4)
PROTHROMBIN-COMPLEX CONCENTRATES IN LIVER DISEASE (1975) (4)
Use of Lipid-Lowering Drugs and Associated Outcomes According to Health State Profiles in Hospitalized Older Patients (2021) (4)
Thrombotic Thromboytopenic Purpura: Another Example of Immunomediated Thrombosis (2006) (4)
The methodology for defining the European standards for the certification of Haemophilia Centres in Europe. (2014) (4)
Ischemic stroke in congenital (type II C) defective antithrombin III (1993) (4)
Genetic testing in von Willebrand disease: a rebuttal (2010) (4)
Solicited self‐referencing undermines the credibility of researchers and journals (2012) (4)
Polycythaemia vera and JAK2 mutation (2007) (4)
Inflammatory bowel disease are not associated with the major hereditary conditions predisposing to thrombosis (1998) (4)
Methods for the detection of activated platelets. (1984) (4)
Screening of thrombophilia in women with failure of embryo implantation: far from being recommended. (2003) (4)
Reply to: The importance and challenge of pediatric trials of hemophilia drugs (2014) (4)
Hyperglycemia at admission, comorbidities, and in-hospital mortality in elderly patients hospitalized in internal medicine wards: data from the RePoSI Registry (2021) (4)
PATHOGENESIS OF VON WILLEBRAND'S DISEASE (1976) (4)
Hemophilia Care in Italy (1976) (4)
Hyperglycemia at admission, comorbidities, and in-hospital mortality in elderly patients hospitalized in internal medicine wards: data from the RePoSI Registry (2021) (4)
Interference of factor V Leiden on protein S activity: evaluation of a new prothrombin time-based assay (2007) (4)
Pseudopathologies of hemostasis and dental surgery. (1991) (4)
282 HIGH INCIDENCE OF HEPARIN INDUCED THROMBOCYTOPENIA (HIT) IN SPLANCHNIC VEIN THROMBOSIS TREATED WITH LOW MOLECULAR WEIGHT HEPARIN (LMWH) (2008) (4)
The More Recent History of Hemophilia Treatment. (2022) (4)
Fibrin(ogen) Peptides in Early Breast Cancer (1989) (4)
International survey of attitudes towards secondary prophylaxis with recombinant factor VIIa in haemophilia A patients with inhibitors (2009) (3)
Clinical and laboratory observations in eight patients with lupus-type circulating anticoagulant. (1979) (3)
Varied immunological reactivity of factor VIII from animal plasmas. (1980) (3)
Vaccine-induced immune thrombotic thrombocytopenia with atypical vein thrombosis: Implications for clinical practice (2022) (3)
Genotypes of European and Iranian patients with type 3 von Willebrand disease enrolled in 3WINTERS-IPS. (2021) (3)
Carrier detection and prenatal diagnosis of hemophilia A: 5-years experience at a hemophilia center (1992) (3)
Two Naturally Occurring Mutations on FVII Gene (S363I-W364C) Altering Intrinsic Catalytic Activity (2002) (3)
The multifaceted spectrum of liver cirrhosis in older hospitalised patients: analysis of the REPOSI registry. (2020) (3)
Platelet abnormalities in renal transplantation. (1981) (3)
FREQUENCY OF FACTOR V LEIDEN AND PROTHROMBIN POLYMORPHISM IN SOUTH OF IRAN (2009) (3)
Impact of Early Factor VIII Exposure, Prophylaxis and Prenatal/Perinatal Events on Inhibitor Risk in Children with Hemophilia A: A Case-Control Study. (2004) (3)
Recombinant human factor VIII (1990) (3)
Risk Factors for Recurrence of Thrombotic Thrombocytopenic Purpura. (2006) (3)
Use of desmopressin in the treatment of hemophilia A: towards a golden jubilee (2018) (3)
Purification and Further Characterization of Antithrombin III Milano: Lack of Reactivity with Thrombin (1987) (3)
Perspective - The case for zero bleeds and drug bioequivalence in the treatment of congenital hemophilia A in 2021. (2021) (3)
Proposal to establish a European Association for Hemophilia and Allied Disorders (2006) (3)
The dark age of Italian general practice research - An Italian matter. (2019) (3)
Platelet Function and Thrombosis (2012) (3)
Effect of adenosine derivatives on in vitro thrombus formation induced by shear stress. (1999) (3)
Prevalence of use and appropriateness of antidepressants prescription in acutely hospitalized elderly patients. (2019) (3)
Carrier detection and feasibility of prenatal diagnosis of hemophilia B by multiplex polymerase chain reaction (1993) (3)
Intracerebral haemorrhage and recombinant factor VIIa: not so good news! (2007) (3)
High incidence of thalassaemia in patients with intraocular haemorrhages. (1969) (3)
Preliminary In Vivo Evaluation of a Nanofiltered Factor IX Concentrate (1995) (3)
Diagnosis and assessment of bleeding tendency in chronic liver failure using three simple coagulation tests. (2009) (3)
The knowledge and perception of factor concentrate in persons with haemophilia A (1995) (3)
Antiplatelet drugs after acute myocardial infarction (1984) (3)
The future of hemophilia treatment. (2004) (3)
Conflicts of interest in medicine: a never-ending story (2020) (3)
Multiple molecular forms of lactatedehydrogenase (LDH) of normal and leukemic cells of the myeloid line. (1966) (3)
Anti-LAV/HTLV-III antibodies in groups of individuals at high risk for infection in Italy (1985) (3)
STRUCTURAL DIVERSITY AMONG CELLULAR ADHESION RECEPTORS: FIBRINOGEN BINDING IS A NOVEL BIOLOGICAL PROPERTY OF THE MONOCYTE DIFFERENTIATION ANTIGEN OKM1 (1987) (3)
Source and Purity of Factor VIII Products As Risk Factors for Inhibitor Development In Previously Untreated Patients with Severe Hemophilia A (2011) (3)
RISTOCETIN AND PLATELET AGGREGATION (1989) (3)
In Vitro Expression Studies of Two Mutations on the Metalloprotease and First Cub Domains of the ADAMTS-13 Gene Leading to Severe ADAMTS-13 Deficiency and Chronic Recurrent TTP. (2004) (3)
Detection of Non Inhibitory Binding Antibodies to Von Willebrand Factor Affecting the Clearance of VWF:Ag in Von Willebrand Disease (2011) (3)
Molecular Basis of von Willebrand Disease Type (2013) (3)
Prophylaxis of venous thromboembolism in elderly patients with multimorbidity Maura MarcucciAlfonso IorioAlessandro NobiliMauro TettamantiLuca PasinaCodjo Djignefa Djade • Alessandra MarengoniFrancesco SalernoSalvatore CorraoPier Mannuccio Mannucci • REPOSI (REgistro POliterapie SocietaItaliana di M (2013) (3)
Long COVID: A patient perspective (2021) (3)
[The isoenzymes of lactate dehydrogenase and glutamic-oxalacetic transaminase in fetal and adult muscle and muscle of subjects affected by the Duchenne type of progressive muscular dystrophy]. (1965) (3)
The β-Thromboglobulin Test (1980) (3)
Increased Thrombin Generation in Severe Hemophiliacs with Mild Clinical Phenotype (2008) (3)
New therapies for von Willebrand disease. (2019) (3)
Reply to the letter by Iorio (2017) (3)
Chapter 48. Treatment of Von Willebrand Disease: Desmopressin (2007) (3)
A certification/accreditation model for Haemophilia Centres in Italy. (2014) (3)
Replacement therapy and local measures for dental extractions in haemophiliacs: comparison of various schemes of treatment. (1971) (3)
Bleeding Disorders in Primary Fibrinolysis (2021) (2)
Risk of Inhibitor Development after Intermediate Purity Coagulation Factor Concentrates: Is It Truly Low? (1995) (2)
Homeopathy provided by a national health service: Only in Italy? (2017) (2)
The search of a common path in internal medicine. (2012) (2)
Pharmacokinetic Evaluation of a Fibrinogen Concentrate in Patients with Congenital Fibrinogen Deficiency. (2008) (2)
Traffic-related air pollution and the coronavirus pandemia: shadows and lights. (2020) (2)
BLOOD FRACTIONS FOR HÆMOPHILIA (1974) (2)
The Molecular Basis of Von Willebrand Disease (2010) (2)
Gout, allopurinol intake and clinical outcomes in the hospitalized multimorbid elderly. (2014) (2)
Problems in hemophilia therapy (1981) (2)
Laboratory measures of hemostasis for monitoring liver graft function. (1993) (2)
Thrombotic Thrombocytopenic Purpura and Haemolytic–Uraemic Syndrome (Congenital and Acquired) (2007) (2)
Factor V Leiden mutation in patients with breast cancer and a central venous catheter: Relationship with deep vein thrombosis. (2004) (2)
20 Years Desmopressin (DDAVP) in the Treatment of Bleeding Disorders: The First (2011) (2)
Global Forum of the World Federation of Hemophilia, September 26-27, 2005, Montreal, Quebec, Canada. (2006) (2)
Clinical risk scores for the early prediction of severe outocomes in patients hospitalized for COVID-19: comment (2021) (2)
Thromboembolism Following Prothrombin Complex Concentrates and Major Surgery in Severe liver Disease (1978) (2)
Prevalence of pancreatic disorders in HIV-infected hemophiliacs: diagnostic methods and their clinical significance. (1994) (2)
Determinants of coagulation activation in humans. (1996) (2)
Reply to: Endogenous heparinoids contribute to coagulopathy in patients with liver disease (2008) (2)
Delta infection among haemophiliacs. (1983) (2)
Aspirin as antiplatelet agent in diabetes: Cons. (2010) (2)
Underdiagnosis and undertreatment of osteoporotic patients admitted in internal medicine wards in Italy between 2010 and 2016 (the REPOSI Register) (2021) (2)
Platelet function and thrombosis : a review of methods : proceedings of a postgraduate course held at the Fondazione Lorenzini in Milan, Italy, February 24-26, 1972 (1972) (2)
Increased Thrombin Generation in Inflammatory Bowel Diseases (2008) (2)
Mechanism of the Prolonged Bleeding Time in yon Willebrand’s Disease (vWd) (1975) (2)
An improved method for measuring red blood cell filterability (1985) (2)
Progressive decrease of the healthcare impact of the post‐COVID condition after the first disease wave in Lombardy, Italy (2022) (2)
Diagnosis of hemophilia a in a female subject by using restriction fragment length polymorphisms linked to the factor VIII gene (1989) (2)
Frequency of Antiphospholipid Antibodies in Iranian Patients with Solid Malignan-cies: A Pilot Study (2009) (2)
An ecological alliance against air pollution and cardiovascular disease (2022) (2)
Ex vivo experimental thrombosis in variants of von Willebrand disease. (1993) (2)
Association between air temperature, air pollution and hospital admissions for pulmonary embolism and venous thrombosis in Italy. (2021) (2)
Appropriateness of antithrombotic prophylaxis in the oldest old with non-valvular atrial fibrillation: ARAPACIS and REPOSI. (2015) (2)
Pharmaceutical pricing in Europe: time to take the right direction (2022) (2)
Heart failure and chronic kidney disease in a registry of internal medicine wards (2014) (2)
Symposium in memory of Professor Inga Marie Nilsson (2001) (2)
Heart failure and chronic kidney disease in a registry of internal medicine wards (2014) (2)
Proceedings: Mechanisms of the prolonged bleeding time in von Willebrand's disease (vWd). (1975) (2)
αIIbG236E causes Glanzmann thrombasthenia by impairing association with β3 (2008) (2)
Orthopaedics and Haemophilia (1981) (2)
alpha 1-Antitrypsin therapy in a case of thrombotic thrombocytopenic purpura. (1995) (2)
Effect of Inhibitors of Aggregation on Platelet Ultrastructure in Vitro (1969) (2)
Lactate dehydrogenase (LDH), glutamic oxalacetic transaminase (GOT) and malate dehydrogenase (MDH) isoenzymes in lymphocytes from foetal and adult thymus, spleen and from peripheral blood. (1966) (2)
DETERMINATION OF ANTI-ADAMTS13 AUTOANTIBODIES IN THROMBOTIC TROMBOCITOPENIC PURPURA (TTP) PATIENTS: COMPARISON OF TWO DIFFERENT METHODS (2007) (2)
Factor VIII inhibitor and source of replacement therapy. (2012) (2)
Lecture: Abnormalities of Haemostasis Tests in Chronic Liver Disease: Clinically Relevant? (2007) (2)
Few platelets, many platelets: the role of the internist (2000) (2)
P. Gresele, C.P. Page, V. Fuster and J. Vermylen (eds). Platelets in Thrombotic and Non-Thrombotic Disorders: Pathophysiology, Pharmacology and Therapeutics (2003) (2)
The Rokitanski-Duguid Project (1981) (2)
Automated amidolytic method for evaluating the activated partial thromboplastin time compared with a conventional coagulation method. (1989) (2)
IMPACT OF RECOMBINANT FACTOR VIII! ON HEMOPHILIA CARE (1994) (2)
Prognostic value of the activated partial thromboplastin time after orthotopic liver transplantation: a prospective study. (1994) (2)
Studies with the Nanobody That Detects the Gain-of-Function of von Willebrand Factor in a Cohort of Patients with Type 2B von Willebrand Disease: Correlation with Platelet Count, VWF Multimers and Molecular Defects. (2006) (2)
[The hematologist]. (1997) (2)
Fibrinogen as a Model Protein in Epidemiological Studies (1993) (2)
Clinical Severity, Age, and Sex Overcome Cardiometabolic Morbidities but Not Stroke as Predictors of Mortality in Elderly Inpatients: Data From the REgistro POliterapie Società Italiana di Medicina Interna Registry (2016) (2)
A study on blood coagulation factors, fibrinolysis and platelet function in workers exposed to carbon disulfide (1981) (2)
Author Index/Subject Index (2018) (2)
Restriction of Polymerase Chain Reaction Products for Carrier (1990) (2)
Synovectomy Revisited (1977) (2)
Increased Ristocetin Induced Binding of Factor VIII to Platelets in Von Willebrand’s Disease (vWd) (1979) (2)
QL8 QUALITY OF LIFE IN HEMOPHILIC PATIENTS WITHOUT INHIBITORS: THE COCHE STUDY (2005) (2)
Convalescent plasma for administration of passive antibodies against viral agents (2020) (2)
Posters. pp 247–288 (2010) (2)
HAEMOPHILIA CARE IN DEVELOPING COUNTRIES (1980) (2)
Sustained Suppression of Hepatitis C by Pegylated Interferon and Ribavirin in Hemophilic Patients. (2004) (1)
Desmopressin in the Treatment of Congenital and Acquired Defects of Platelet Functions (1993) (1)
Clinico-Pharmacological Studies of Factor VIII Response After DDAVP (1979) (1)
THE PAST AS PROLOGUE — CIRRHOSIS AS THE EPITOME OF THE HEMORRHAGIC DISEASES ? (2016) (1)
DDAVP : A New Pharmacologic Approach to the Management of Hemophilia and Von Willebrand’s Disease (1977) (1)
Use of non-steroidal anti-inflammatory drugs and analgesics in a cohort of hospitalized elderly patients: Results from the REPOSI study. (2017) (1)
Abstract 4882: Factor V Leiden, But Not Prothrombin G20120A, Is Associated With Premature Myocardial Infarction (2008) (1)
Effects on bleeding complications of pharmacogenetic testing for initial dosing of vitamin K antagonists: a systematic review and meta‐analysis: reply (2015) (1)
Q222R polymorphism in the DNAse I gene is not associated with susceptibility to rheumatoid arthritis or to disease course in an Argentine patient cohort (2016) (1)
Risk Differential in Inhibitor Development in the First Days of Treatment By Product Class: A Sippet Analysis (2016) (1)
Activated partial thromboplastin time: results of a case–control study evaluating six commercial reagents in assessing the risk of venous thromboembolism (2006) (1)
What changed in the Italian internal medicine and geriatric wards during the lockdown (2020) (1)
Three novel PROC gene lesions causing protein C deficiency (1998) (1)
Acute promyelocytic leukemia with unusual morphological features, absence of the t(15,17) and rearranged PML/RAR alpha genes. (1994) (1)
Aspirin (ASA) Inhibits both Prostacyclin and Thromboxane Formation in Man (1979) (1)
Reply: Interaction between inherited thrombophilia and HIV infection: fact or fancy? (2014) (1)
Reduced FVIII recovery associated with anti-FVIII PEG antibodies after BNT162b2 SARS-CoV-2 vaccination (2022) (1)
Screening for hemostasis during hemorrhagic emergencies (1989) (1)
Chlorpropamide alcohol flush (CPAF), diabetic renal and retinal lesions in non-insulin-dependent diabetics (NIDD), distribution of lesion-related risk factors (1981) (1)
Autoimmune bleeding disorders in cancer patients. (2001) (1)
A chromogenic assay of prothrombin compared with coagulation tests during anticoagulant therapy and liver disease (1981) (1)
CHAPTER 67 – Desmopressin (DDAVP) (2007) (1)
Coronary Heart Disease / Myocardial Infarction Diminished Vascular Response to Inhibition of Endothelium-Derived Nitric Oxide and Enhanced Vasoconstriction to Exogenously Administered Endothelin-1 in Clinically Healthy Smokers (2005) (1)
Molecular forms of lactic dehydrogenase of fava bean-sensitive subjects. (1965) (1)
Prescription appropriateness of anticoagulant drugs for prophylaxis of venous thromboembolism in hospitalized multimorbid older patients (2022) (1)
Letter: Clotting factors in von Willebrand's disease. (1974) (1)
289 Comparison of methods for t-PA and PAI activity used for evaluation of response to venous occlusion (1988) (1)
Fibrinogen and factor VII as risk factors for ischemic heart disease (1995) (1)
Treatment of VWD Patients Requiring Elective Surgery with a Pasteurized von Willebrand Factor/FVIII Concentrate (Haemate®P) - The Use of a PK Guided Approach. (2005) (1)
Atherosclerosis and thrombophilia. (1980) (1)
Mutational Repertoire in the SIPPET Cohort and Prediction of FVIII Inhibitor Risk (2017) (1)
Decisions and dilemmas: resolving ethical, medical and economic issues facing haemophilia care (2001) (1)
ADAMTS13 Content of Plasma-Derived Factor VIII-Von Willebrand Factor Concentrates (2012) (1)
Response to “Innovation in Hemophilia Therapies—‘And Miles to Go, before [We] Sleep’” (2016) (1)
Monitoring Warfarin Therapy in Patients with Lupus Anticoagulants (LA) (1998) (1)
Frequency of antiphosholipid antibodies in Iranian patients with solid malignancies: a pilot study. (2009) (1)
Blood-borne viral infections in patients with von Willebrand disease: Prevalence and clinical correlation (2000) (1)
Risk of myocardial infarction and polymorphisms in candidate genes. (2003) (1)
Von Willebrand factor propeptide and pathophysiological mechanisms in European and Iranian patients with type 3 von Willebrand disease enrolled in the 3WINTERS‐IPS study (2022) (1)
Increase of Fibrinopeptide a After Concentrates of the Prothrombin Complex (1979) (1)
DDAVP in the Management of Congenital and Acquired Bleeding Disorders: Solved and Unsolved Issues (1993) (1)
Relation between drug therapy-based comorbidity indices, Charlson's comorbidity index, polypharmacy and mortality in three samples of older adults. (2022) (1)
Significance of Reduced Protein C in Patients with Acute Stroke and Unfavourable Prognosis (1988) (1)
Correction to: Hyperglycemia at admission, comorbidities, and in-hospital mortality in elderly patients hospitalized in internal medicine wards: data from the RePoSI Registry (2021) (1)
ON THE DISCREPANT POST‐DDAVP INCREASE OF FVIII:C AND VON WILLEBRAND FACTOR IN SOME PATIENTS WITH SEVERE VON WILLEBRAND'S DISEASE (1995) (1)
Identification of genetic risk variants for deep vein thrombosis by multiplexed next-generation sequencing of 186 hemostatic/pro-inflammatory genes (2012) (1)
Impact of HIV and its treatment on chronic hepatitis C in hemophiliacs (1994) (1)
Relationships between metabolic and hemostatic variables in uncomplicated diabetes (1981) (1)
Deamino d arginine vasopressin (DDAVP): effects on factor VIII related properties in von Willebrand's disease (vWd) (1974) (1)
Prevention and treatment of major blood loss - Reply (2007) (1)
Comparison of quality of life, and emotional and functional profiles in older people with and without severe haemophilia (2021) (1)
Why so many different specialty training programmes in general practice in Europe? (2022) (1)
Response: Anticoagulation in splanchnic vein thrombosis (2009) (1)
Acquired Storage Pool Deficiency in Platelets during DIC (1975) (1)
UH1 COST AND QUALITY OF LIFE OF HEMOPHILIA: COMPARISON BETWEEN PATIENTS WITH AND PATIENTS WITHOUT INHIBITORS (2005) (1)
PROTHROMBIN MUTANT REVEALS AN UNEXPECTED INFLUENCE OF THE A-CHAIN ’ S STRUCTURE ON THE ACTIVITY OF HUMAN α-THROMBIN (2004) (1)
Circulating anticoagulants in haemophilia. (1970) (1)
ANTIBODIES TO TISSUE-TYPE PLASMINOGEN ACTIVATOR (tPA) IN PATIENTS WITH ANTIPHOSPHOLIPID SYNDROME. EVIDENCE OF INTERACTION BETWEEN THE ANTIBODIES AND THE CATALYTIC DOMAIN OF tPA IN TWO PATIENTS Anti-tPA antibodies in antiphospholipid syndrome (2003) (1)
Successful Calibration of a Reagent from Human Placenta against rTF/95, the WHO International Reference Preparation for Thromboplastin, Human Recombinant, Plain (1998) (1)
Plasma Prothrombin Levels are not Associated with Mutations in the Promoter Region of the Prothrombin Gene (2002) (1)
PS-061 The recognition/reconciliation process in elderly patients: a retrospective study in geriatric and internal medicine wards (2015) (1)
[The role of erythrocyte deformability in the prolonged bleeding time in liver disease patients]. (1985) (1)
Thrombin Generation in Severe Hemophiliacs with Different Clinical Phenotype. (2006) (1)
Getting rid of refractory hemophilia. (2012) (1)
Pharmaceutical patenting in the European Union: reform or riddance (2021) (1)
Alterations in fibrinolysis and blood coagulation. (1969) (1)
associated with a prolonged bleeding time Controlled trial of desmopressin in liver cirrhosis and other conditions (2011) (1)
IgG subclasses as biomarkers for persistence of factor VIII inhibitors in previously untreated patients with severe haemophilia A (2020) (1)
Functional analysis of missense mutations in the Myocyte Enhancer Factor 2A (MEF2A) gene do not support their causal role in the pathogenesis of myocardial infarction (2008) (1)
Factor VIII Related Properties in Platelets of Patients with von Willebrand’s Disease (VWD) (1977) (1)
Treatment of Von Willebrand Disease: Desmopressin (2014) (1)
Genetic Risk Stratification to Minimize Inhibitor Risk with the Use of Recombinant Factor VIII Concentrates: A Sippet Analysis (2016) (1)
Authors’ Reply to Brunetti et al. “Potentially Inappropriate Medications, Drug–Drug Interactions, and Anticholinergic Burden in Elderly Hospitalized Patients: Does an Association Exist with Post-Discharge Health Outcomes?” (2020) (1)
HLA antigens in hemophiliacs with long term non progressive HIV infection (1996) (1)
Subject Index, Vol. 26 (suppl 1), 1996 (1996) (1)
How to Get Started: Problems in the Third World (1981) (1)
Fibrinogen Milan II: A congenital dysfibrinogenemia with a defective clotting by thrombin, normal clotting by arvin, reptilase and prothrombin-staphy1ocoagulase complex, associated with thrombotic episodes (1985) (1)
At the end of the first 3 years (2007) (1)
Community and hospital pharmacists in Europe: encroaching on medicine? (2020) (1)
Gene transfer in hemophilia A: not cogent yet (2022) (1)
More on air pollution and venous thromboembolism. (2017) (1)
Tissue factor antigen and activity in unstable coronary plaques (1998) (1)
Intracranial bleeding in haemophilia. A study of eleven cases. (1983) (1)
More on: Properties of recombinant human thromboplastins that determine the International Sensitivity Index (ISI) (2005) (1)
Thrombotic thrombocytopenic purpura and other immune mediated blood disorders following SARS-CoV-2 vaccination. (2021) (1)
DATABASE ON RARE BLEEDING DISORDER (RBDS): PHENOTYPE AND GENOTYPE ANALYSIS ON 400 AFFECTED PATIENTS (2007) (1)
Hypercoagulability in Acute Stroke and its Prognostic Significance (1987) (1)
[Hemophilia 1989: light and shadow]. (1989) (1)
William Hewson and the blood which issued last but clotted first: the beginning of the story of desmopressin in haemophilia and vWD (1996) (1)
Multicentre evaluation of Normotest performance characteristics Interlab variation, comparison of manual and instrumental techniques, reproducibility, normal range (2009) (1)
Vascular And Platelet Effects Of Synthetic Analogues Of Prostacyclin (1981) (1)
Fibrinogens “Milano II” - and “Naples” (1987) (1)
Different Types of von Wiilebrand’s Disease (vWd): A Study of 101 Cases (1975) (1)
Fibrinogen In Liver Cirrhosis. Lack Of Correlation Between Soluble Fibrin Monomer Complexes And Fibrinopeptide A Levels (1981) (1)
Clinical Trials of Recombinant Factor VIII (1991) (1)
Letter: Concentrates of clotting-factor IX. (1976) (1)
New antiplatelet agents in acute coronary syndromes (ACS): an update. (2010) (1)
Microparticle Levels Are High in Patients with Hemophilia A and Can Be Further Increased by DDAVP Administration. (2007) (1)
Combined estrogen-progestin oral contraceptives [letter] (2004) (1)
DEVELOPMENT AND MORPHOLOGY OF THE SKULL IN THE DIK-DIKS (GENUS MADOQUA OGILBY, ARTIODACTYLA BOVIDAE) (1982) (1)
The incidence of venous thromboembolism in asymptomatic carriers of antithrombin, protein C or protein S: a prospective cohort study. (1999) (1)
[An automatic method for determination of euglobulin lysis time]. (1973) (1)
Letter: F.D.P. levels in intravascular haemolysis. (1973) (1)
PS-060 Agreement between potential drug interactions identified by an electronic tool and clinical judgment: intercheck versus physicians (2015) (1)
Renal Function, Cardiovascular Diseases, Appropriateness of Drug Prescription and Outcomes in Hospitalized Older Patients (2021) (1)
Molecular characterization of 11 kindred with prothrombin deficiency (1999) (1)
Rate of inhibitor development in previously-untreated hemophilia A patients treated with plasma derived or recombinant factor VIII concentrates. A systematic review of the literature and meta-analysis (2010) (1)
[Considerations on the cholecystokinetic activity of 1-phenyl-1-hydroxy-N-pentane]. (1963) (1)
Treatment of congenital bleeding disorders: future trends in management. (2009) (1)
FIRST TRIMESTER PRENATAL DIAGNOSIS OF HEMOPHILIA A BY COMBINED USE OF DNA PROBES (1987) (1)
Plasma protein S in chronic renal insufficiency. (1991) (1)
The role of Willebrand factor in haemostasis and atherosclerosis (1978) (1)
INCREASED ADHESIVE PROPERTIES OF THE CARBOHYDRATE-MODIFIED VON WILLEBRAND FACTOR (CHO-VWF): CRITICAL ROLE OF THE MULTIMERIC STRUCTURE AND CORRELATION WITH PLATELET AGGREGATION (1987) (0)
P2635Prevalence of appropriate treatment in elderly heart failure patients and impact on clinical outcomes: a subgroup analysis from REPOSI registry (2019) (0)
The Thrombospondin-1 N700S Polymorphism Does Not Alter von Willebrand Factor Multimer Size in Patients Suffering an Acute Myocardial Infarction. (2005) (0)
[An instruction manual for reforming Italian general practice.] (2021) (0)
P6588Long-term relationship between atrial fibrillation and charlson comorbidity index in a population-based cohort study (2018) (0)
Authors Index, Vol. 26, Supplement 4, 1996 (1996) (0)
Pre-Conference Statements: Schnabel, F.: The 1980s (1981) (0)
The α IIbG236E Mutations Causes Glanzmann Thrombasthenia by Impairing Association with β3. (2005) (0)
Factors affecting adherence to guidelines for antithrombotic therapy in elderly patients with atrial ﬁ brillation admitted to internal medicine wards European Journal of Internal Medicine (2010) (0)
The role of general practitioners in the EU: time to draw lessons from a too wide range? (2023) (0)
Recombinant FVIII: the milestone of modern hemophilia treatment (2020) (0)
Chapter 60 – Desmopressin (DDAVP) (2013) (0)
The start of a new era-antithrombotic agents. Abstracts from the 21st International Congress on Thrombosis. July 6-9, 2010. Milan, Italy. (2009) (0)
Haemophilia Centre Certification Systems: optional or optimal choice for healthcare systems? (2014) (0)
Effect on platelet behaviour of beta-benzal-butyric acid. (2009) (0)
Profile of Mutations Identified in the 3WINTERS-IPS Project on European & Iranian Patients with Previously Diagnosed Type 3 Von Willebrand Disease. (2018) (0)
Efficacy and Safety of High-Intermediate-Purity VWF/FVIII Concentrates Given Repeatedly to Severe Patients with Von Willebrand Disease: An Italian Cohort Study on 32 Intensively Treated Cases. (2006) (0)
CHARACTERIZATION OF THE FUNCTIONAL ADHESION PROPERTY OF THE MONOCYTE FIBRINOGEN RECEPTOR WITH A MONOCLONAL ANTIBODY (Mab) DIRECTED TO THE ACTIVATED STATE OF THE PLATELET GLYCOPROTEIN (GP) IIb/IIIa (1987) (0)
Clinical Course of Deep Venous Thrombosis (1997) (0)
Deep Vein Thrombosis during Pregnancy in Double Homozygous Carrier of Factor V Leiden and Prothrombin G20210A. (2005) (0)
Current therapy of von Willebrand's disease: Preface (1994) (0)
Arterio-venous fistula as permanent access for home treatment in children with hemophilia: long-term safety and feasibility (2003) (0)
Drugs Affecting Platelet Behaviour (1976) (0)
Localization and Function of Platelet ADAMTS-13. (2005) (0)
SUBCUTANEOUS AND INTRAVENOUS ADMINISTRATION OF DESMOPRESSIN (DDAVP) TO HEMOPHILIACS: PLASMA PHARMACOKINETICS AND FACTOR VIII (VIII:C) RESPONSES (1987) (0)
NEW INSIGHTS IN ADAMTS13 PHYSIOLOGY BY MEASURING ACTIVITY OVER ANTIGEN RATIO (2007) (0)
Hepatitis B vaccination in hemophiliacs. (1990) (0)
Study Deficiency of Antithrombin, Protein C, or Protein S: A Prospective Cohort The Incidence of Venous Thromboembolism in Asymptomatic Carriers of a (2013) (0)
Comparison of a natural heparinoid with sodium and calcium heparin for their effect on the inhibitor of activated factor X (1976) (0)
[Acute myeloid leukemia: towards a cure?]. (1998) (0)
Current Therapy of von Willebrand’s Disease (1994) (0)
Le coagulopatie immunologiche in Medicina Interna (2001) (0)
An overview of haemostasis, in relation to atherothrombotic, thromboembolic, and venous cardiovascular disease (2018) (0)
Von Willebrand Factor-Glycoprotein Ib-Alpha Interactions Play a Role in Generating Platelet Microparticles: Data from Ex Vivo and in Vitro Studies (2008) (0)
Effect of blood coagulation of massive intravascular haemolysis. (1968) (0)
A novel missense mutation (Thr176→IIe) at the putative hinge of the neo N-terminus of activated protein C (1995) (0)
of action independent of released von Willebrand factor Willebrand disease treated with cryoprecipitate. Evidence for a mechanism DDAVP shortens the prolonged bleeding times of patients with severe von (2011) (0)
[Annali Italiani di medicina interna: present and future]. (1995) (0)
[Low molecular weight heparin: the first 5 years]. (1997) (0)
Molecular characterization of six novel mutations causing factor V deficiency (2008) (0)
Papers to be published in forthcoming issues. Toward more effective antifungal therapy: the prospects of combination therapy (2004) (0)
CLINICAL COURSE OF DEEP VENOUS THROMBOSIS. AUTHORS' REPLY (1997) (0)
Protein C — An Inhibitor of Blood Coagulation: Biochemistry, Physiology, Clinical Aspects (1985) (0)
Clinical features and outcomes of elderly hospitalised patients with chronic obstructive pulmonary disease, heart failure or both (2023) (0)
Using a registry to monitor inhibitor development in haemophilia: first results of EUHASS (2010) (0)
by inhibitors: the COCIS Study Group Cost of care and quality of life for patients with hemophilia complicated (2013) (0)
Air Pollution, Smoking, and Plasma Homocysteine The Harvard community has made this article openly available. Please share how this access benefits you. Your story matters (2007) (0)
Protein C — An Inhibitor of Blood Coagulation: Biochemistry, Physiology, Clinical Aspects (1985) (0)
[Fibrinolytic and defibrinogenation therapy]. (1983) (0)
[Immunologic thrombosis]. (2001) (0)
In vivo inactivation of factor V by a vitamin K-dependent factor. Study of an individual with combined factor V/VIII deficiency. (1983) (0)
Reply to: [Factor XI mutation and the origin of Ashkenazi Jews. Haematologica 2008; 93:e59] (2008) (0)
Genetics of warfarin response. (2008) (0)
Rebuttal to the Letter by T. Exner and R. Dybkaer (1993) (0)
Specificity of the anti-HCV elisa assay in hemophiliacs with persistently normal transaminases (1990) (0)
Recent progress in fibrinolysis. (1979) (0)
Relevance of Chloride Binding to Von Willebrand Factor in Type 2B Von Willebrand Disease Patients. (2008) (0)
Managing prostatic illness in persons with haemophilia (2022) (0)
P4012Antiplatelet therapy and adverse outcomes in high cardiovascular risk elderly patients: a sex and gender focused analysis from REPOSI study (2017) (0)
adenosine diphosphate characterized by severe impairment of platelet responses to Identification of a new congenital defect of platelet function (2011) (0)
The “Diabetes Comorbidome”: A Different Way for Health Professionals to Approach the Comorbidity Burden of Diabetes (2022) (0)
The Proprotein Convertase Subtilisin-Kexin type 9 (PCSK9) R46L variant is associated with reduced serum low-density lipoprotein cholesterol (LDL-C) in the Italian population (2007) (0)
Biochemical Platelet Abnormalities After Renal Transplantation (1981) (0)
gene strategy for the detection of point mutations in the human factor VIII The molecular genetic analysis of hemophilia A : a directed search (2003) (0)
Reply: (2007) (0)
Beta-benzal-butyric acid, a new anti-adhesive drug. (1972) (0)
[Considerations on clinical drug research in Italy]. (2006) (0)
Home care of haemophilia in Italy. (2009) (0)
ISTH and SSC MEETINGS Second Announcement of the XVIth Congress of the ISTH (2010) (0)
Clinical governance: many fancies, very few facts (2012) (0)
The Influence of F8 Mutation and Thrombophilic Genetic Markers on Bleeding Phenotype of Patients Affected with Severe Hemophilia A in the SIPPET Cohort (2017) (0)
Prospective stuty on acute thrombotic microangiopathy (TMA) afetr bone marrow transplantation (BMT) : role of ADAMTS 13, WWF : Ag and high molecular weight Von Willebrand factor (HMW:VWF) (2005) (0)
[Behavior of cytoplasmatic and mitochondrial glutamic oxalacetic transaminase in the serum of subjects affected by acute viral hepatitis of diverse evolution]. (1965) (0)
[Characterization of glutamic-oxalacetic transaminase in normal and leukemic human lymphocytes]. (1965) (0)
Bleeding and haemostasis disorders (2018) (0)
Understanding hemostasis and thrombosis : The lesson learnt from natural models (2008) (0)
The search for the causes of myocardial infarction. Introduction. (2001) (0)
Anti-COVID-19 vaccines and rare cases of cerebral venous sinus thrombosis with thrombocytopenia: what about the pragmatic benefit/risk evaluation for still unvaccinated young women (2022) (0)
Rokitanski-Duguid Proiect on Thrombosis and Hemostasis (1985) (0)
The First Deletion Mutation in the TSP1-6 Repeat Domain of ADAMTS13 Leads to a Secretion Defect. (2005) (0)
Contents, Vol. 11, 1982 (1982) (0)
Low serum albumin is associated with mortality and arterial and venous ischemic events in acutely ill medical patients. Results of a retrospective observational study. (2023) (0)
High Efficacy of Combination Therapy with Pegylated Interferon and Ribavirin in Hemophiliacs with Chronic Hepatitis C. (2005) (0)
Comprar Thrombosis. The Start Of A New Era For Antithrombotic Agents (Pathophysiology Of Haemostasis And Thrombosis, Vol. 37 Suppl. 1) | Mannucci, P.M. | 9783805593885 | Karger AG (2010) (0)
The European Journal of Medicine: Behind the curtains (2015) (0)
Identification of DEEP Vein Thrombosis GENETIC RISK Variants by NEXT GENERATION Sequencing of Hemostatic Genes (2011) (0)
Circulating Versus Progenitor Endothelial Cells Levels Are Abnormal in Patients with Different Types of Von Willebrand Disease and Correlate with Markers of Angiogenesis (2008) (0)
[Molecular forms of malate dehydrogenase (MDH) infetal and adult thymic and splenic lymphocytes]. (1966) (0)
The Impact of the First Exposure to Different Blood Products on the Prevalence and Natural History of Hepatitis C Virus Infection in Von Willebrand Disease (VWD): Results from a Large Cohort Study Comparing VWD and Hemophilia Patients. (2004) (0)
[Hemophilia therapy in Italy: what the near future promises.] (2023) (0)
the liver of plasma protein C predicts the development of venocclusive disease Naturally occurring anticoagulants and bone marrow transplantation (2011) (0)
VON WILLEBRAND FACTOR MULTIMERS IN CULTURED HUMAN ENDOTHELIAL CELLS: COMPARISON BETWEEN CELLULAR STORAGE POOL AND SUPERNATANT (1987) (0)
Ddavp-Induced Alterations In The Multimeric Composition Of Factor Viii/Von Willebrand Factor In Normal And Von Willebrand’S Disease Plasma (1981) (0)
Chronic treatment with betablockers for the management of portal hypertension: A multi-center cross-sectional study in elderly patients with cirrhosis (2014) (0)
[Intermediate thalassemia: a new condition associated with hypercoagulability]. (2000) (0)
PROTEIN C LEVELS DURING THE FIRST MONTH OF LIFE (1984) (0)
ACUTE PROMYELOCYTIC LEUKEMIA WITH UNUSUAL MORPHOLOGICAL FEATURES , ABSENCE OF THE t ( 15 , 17 ) AND REARRANGED PML / RAR a GENES (2005) (0)
Subjects Index, Vol. 26, Supplement 4, 1996 (1996) (0)
Coagulation and blood transfusion : proceedings of the Fifteenth Annual Symposium on Blood Transfusion, Groningen, 1990 (1991) (0)
Title Page / Table of Contents / Foreword (2010) (0)
How I treat How I treat patients with von Willebrand disease (2001) (0)
Antiplatelet Agents in Acute Myocardial Infarction and in the Post-infarction Period. (1993) (0)
[Some metabolic aspects of acquired defects of the release reaction (acquired storage pool deficiency)]. (1978) (0)
What's New in Treatment of Von Willebrand Disease (2019) (0)
PA.145 INCREASED THROMBIN GENERATION IN INFLAMMATORY BOWEL DISEASES (2008) (0)
Proceedings: New synthetic derivatives of natural cyclic nucleotides: their effect on platelet behaviour. (1975) (0)
Characterization of productive and unproductive mRNA splicings in F11 : identification of a novel coagulation FXI isoform (2008) (0)
In Vivo Effect of Cyclic AMP and Related Drugs on Platelet Function (1977) (0)
[Medical aspects of thrombosis of the limbs]. (1991) (0)
Health technology assessment for pharmaceuticals in the European Union: what lessons after two decades? (2022) (0)
Posters. pp 159–202 (2010) (0)
Letter: Pathogenesis of von Willebrand's disease. (1976) (0)
New Sinthetic Derivatives of Natural Cyclic Nucleotides: Their Effect on Platelet Behaviour (1975) (0)
[Proceedings: Trends in laboratory diagnosis of coagulation disorders]. (1973) (0)
[CHROMATOGRAPHIC AND ELECTROPHORETIC CHARACTERIZATION OF MALATE DEHYDROGENASE (MDH) IN THE SERUM AND LIVER TISSUE OF NORMAL SUBJECTS AND PATIENTS WITH ACUTE HEPATITIS]. (1965) (0)
Hemophilia treatment innovation: 50 years of progress and more to come. (2023) (0)
A Randomized Crossover Study of High- and Standard-Dose Recombinant Factor VIIa for Treatment of Hemarthroses in Hemophiliacs with Inhibitors. (2005) (0)
Clinical course of deep venous thrombosis [7] (multiple letters) (1997) (0)
[Proceedings: Therapy of hemophilia A and B]. (1973) (0)
Pre-Conference Statements: Maurer, M.H.: First International Haemophilia Conference (1981) (0)
ReFacte (R) and Advate (R): A single-dose, randomized, two-period crossover pharmacokinetics study in patients with hemophilia A (2006) (0)
Antiplatelet therapy in the prevention of cardiovascular diseases. (1993) (0)
[Thrombocythemias (author's transl)]. (1979) (0)
A Multicentre Study on 100 Cases with Thrombotic Thrombocytopenic Purpura: The Role of Adamts-13 Activity and Anti-Adamts-13 Antibodies. (2004) (0)
I16 Hemophilia (2007) (0)
Making clinical decisions on the basis of RODIN (2014) (0)
Patient Preferences for Treatment Products in Hemophilia: A Conjoint Analysis (Conan Study Group). (2004) (0)
A Poor Response to Desmopressin Is Observed in Patients with Mild Hemophilia a and No Detectable FVIII Mutation. (2008) (0)
HEREDITARY THROMBOPHILIA CAUSED BY MISSENSE MUTATION IN PROTEIN C GENE (1987) (0)
Patients with chronic liver disease. Are they naturally anticoagulated? (2022) (0)
Air Pollution and Cardiovascular Health in Middle East and North Africa: Many Shadows but Some Light. (2022) (0)
Chairmen and Participants (1981) (0)
Virus safety of plasma derivatives (1990) (0)
Relationship between CYP2C9 and VKORC1 polymorphisms and anticoagulant dose requirement (2005) (0)
Platelet Mitochondrial Potential and Function Is Altered During Severe Septic Shock. (2009) (0)
Markedly Reduced FVIII Recovery Associated with Anti-FVIII Peg Antibodies after BNT162b2 Sars-Cov-2 Vaccination (2022) (0)
Clustering of Bleeding Symptoms in Patients Previously Diagnosed As Type 3 Von Willebrand Disease: Results from a Large Cohort of Type 3 Von Willebrand Disease (the 3Winters-Ips Project) (2018) (0)
Oral Surgery in Hemophilia with Cryoprecipitate Associated with EACA and Conjugated Estrogens (1972) (0)
Title Page / Table of Contents, Vol. 26, Supplement 1, 1996 (1996) (0)
The Use of High Resolution Melting (HRM) Analysis for Molecular Gene Defects of Type 3 Von Willebrand Disease: Studies of An Italian Cohort of 10 Patients. (2009) (0)
DESMOPRESSIN IN THE TREATMENT DISORDERS (2012) (0)
POST-TRANSFUSION HEPATITIS AFTER PROTHROMBIN COMPLEX CONCENTRATES (1979) (0)
Clinical efficacy and safety of DDAVP with or without tranexamic acid in inherited VWD: final results of the prospective and international study on 229 patients (2013) (0)
Introduction and overview. (2018) (0)
Prenatal diagnosis and carrier detection of hemophilia A. (1991) (0)
Response: Comparing joint arthroplasties in severe hemophilia A with severe hemophilia B (2009) (0)
P0157 : Adherence and safety of beta-blockers in elderly patients with cirrhosis and portal hypertension: A multi-center cross-sectional study (2015) (0)
The risk of venous thromboembolism in family members with mutations in the genes of factor V or prothrombin or both (2000) (0)
Transient Elastography (Fibroscan®) In Adult Patients with Inherited Bleeding Disorders and Chronic Hepatitis C. (2010) (0)
von Willebrand Disease "Vicenza" With Larger-Than-Normal (Supranormal) von (2016) (0)
A plasmin-like, neutral, calcium dependent protease is responsible for the loss of the high molecular weight (HMW) multimers in the carbohydrate (CHO) modified von Willebrand factor (VWF) (1986) (0)
ASIC — LIVER , PANCREAS , AND BILIARY RACT n Imbalance of Pro-vs AntiCoagulation Factors in Plasma From atients With Cirrhosis (0)
To the editor : Deficiency of ADAMTS 13 and thrombotic thrombocytopenic purpura (0)
Pre-Conference Statements: Inwood; M.J.: The Haemophiliacs Blueprint of the Eighties (1981) (0)
Predictive value of fibrinogen in arterial thrombosis (1990) (0)
Reply: Risk Factors for Deep Venous Thrombosis of the Upper Extremities (1997) (0)
FIBRINOGEN IN LIVER CIRRHOSIS. LACK OF CORRELATION BETWEEN SOLUBLE FIBRIN MONOMER COMPLEXES AND FIBRINOPEPTIDE A LEV VARIANT WITH ABNORMAL GAMMA CHAIN : (2018) (0)
The three I hemophilic study: a comparative study of the morbidity pattern between Asian Indian, Iranian and Italian PWH (2003) (0)
A tale of two societies (2006) (0)
Letter regarding article by Martinelli et al, “Risk factors and recurrence rate of primary deep vein thrombosis o the upper extremities” : response (2005) (0)
[Retinal vascular changes and haemostatic function in young patients (author's transl)]. (1981) (0)
National Status Reports (Poster Presentation) (1981) (0)
The Common Variant Rs9939609 In The FTO Gene Is Associated With Early-onset Myocardial Infarction (ABSTRACT). (2008) (0)
Current Therapy of von Willebrand's Disease: Symposium, Mexico City, April 1994: Proceedings (1994) (0)
Causes of death among the cohort of Italian hemophiliacs with HIV infection (1999) (0)
Non-Sense-Mediated mRNA Decay in ADAMTS13 Gene Caused by 29 Nucleotide Deletion. (2006) (0)
ABO blood group and venous thromboembolism a ) Single studies (2017) (0)
A coagulation quality control program in Italy. (2009) (0)
Title Page / Table of Contents / Preface (2003) (0)
Low-Dose Heparin for Prevention of Deep-Vein Thrombosis in Patients Undergoing Hip-Arthroplasty (1975) (0)
PITFALLS OF PROTEIN C ASSAYS IN PATIENTS WITH ACTIVATED PROTEIN C RESISTANCE : REPLY (1996) (0)
Congenital Bleeding: Autosomal Recessive Disorders (2007) (0)
[Thrombolytic therapy in acute myocardial infarct: preliminary results of a controlled clinical trial with streptokinase]. (1971) (0)
DISLIPIDEMIE E PROCESSI EMOCOAGULATIVI (1973) (0)
Low Protein Z Levels and the Risk of Venous Thrombosis. (2005) (0)
Short-term effects of particulate matter concentrations on Pulmonary Embolism and Deep Vein Thrombosis at national level in Italy (2020) (0)
The clinical benefits of ultra-pure replacement factor therapy: Discussion (1990) (0)
Comparison of Commercial ELISA Methods for the Measurement of Prothrombin Fragment 1 + 2 - Rebuttal (1995) (0)
The first year (2004) (0)
Anticoagulation in splanchnic vein thrombosis (2009) (0)
Familial Overexpression of b Antithrombin Caused by an Asn 135 Thr Substitution (1999) (0)
Von Willebrand Disease (vWd) Characterized by Increased Ristocetin Aggregation: A Study of Eleven Cases (1975) (0)
Questions and Answers – Workshop on Comprehensive Care (Workshop I) (2004) (0)
TIPS in hereditary hemorrhagic telangiectasia: Never say never (2008) (0)
Prevalence and Determinants of Bleeding in Severe Von Willebrand Disease Type 3: Results of Retro/Prospective Studies in a Cohort of 105/52 Italian Patients. (2009) (0)
[Characterization of malate dehydrogenase in normal and leukemic human lymphocytes]. (1965) (0)
The role of the Myocyte Enhancer Factor 2A (MEF2A) gene in the pathogenesis of myocardial infarction (2007) (0)
[ELECTROPHORETIC CHARACTERIZATION OF ISOENZYMES OF MALATE DEHYDROGENASE (MDH) IN LIVER TISSUE AND IN BLOOD OF SUBJECTS AFFECTED BY ACUTE HEPATITIS]. (1964) (0)
von Willebrand factor neutralizing and non-neutralizing alloantibodies in 213 subjects with type 3 von Willebrand disease enrolled in 3WINTERS-IPS. (2023) (0)
Long-term follow-up of randomized trials of immediate versus deferred zidovudine in symptom-free HIV infection. Joint Concorde and Opal Coordinating Committee. (1998) (0)
Circulating versus progenitor endothelial cells are abnormal in patients with different types of von willebrand disease and correlate with markers of angiogenesis : a cohort study of 74 cases” (2009) (0)
Abstract 4880: The Common Variant Rs9939609 In The FTO Gene Is Associated With Early-onset Myocardial Infarction (2008) (0)
[Oral and general surgery in hemophiliacs]. (1969) (0)
Type of Factor VIII Product as Inhibitor Risk Factor in Patients with Severe Hemophilia A and Null Mutations. (2009) (0)
[Physical and sports activity: a panacea for all ills?]. (1999) (0)
Subject Index, Vol. 11, 1982 (1982) (0)
How we manage cardiovascular disease in patients with hemophilia. (2023) (0)
Newer fibrinolytic agents in patients with acute myocardial infarction (1986) (0)
Post-COVID condition: dispensation of drugs and diagnostic tests as proxies of healthcare impact (2023) (0)
Availability of plasma fractions for therapeutic use in Italy (1983) (0)
P4517Heart failure in elderly and very elderly hospitalized patients: an epidemiological analysis from the REPOSI registry (2019) (0)
[Behavior of glutamic-oxalacetic transaminase in normal human myelocytes and granulocytes and in myeloid leukemia cells]. (1965) (0)
[Natural anticoagulants as a cause of hereditary familial thrombosis]. (1990) (0)
Pharmacokinetic Behavior of IB1001, An Investigational Recombinant Factor IX, in Patients with Hemophilia B: Repeat Pharmacokinetic Study and Subgroup Analysis (2011) (0)
Factor VIII/Von Willibrand Factor Is An Integral Component Of The Platelet Surface (1981) (0)
Study of the thrombin generation in patients with liver cirrhosis (2005) (0)
ADAMTS-13 Binds Platelets through Gpib. (2009) (0)
Mutational screening of 25 unrelated FV-deficient patients from six countries (2009) (0)
Significance of Abnormal Liver Function Tests in Hemophiliacs: A Follow-Up Study (1977) (0)
Thrombotic thrombocytopenic purpura and other immune-mediated blood disorders following vaccination against SARS-CoV-2 (2021) (0)
Reply to: Is platelet transfusion necessary in cirrhotic patients with splenomegaly? (2014) (0)
Viral Safety of Factor VIII Concentrates (1994) (0)
Pharmacokinetic Analysis of a von Willebrand Factor/Factor VIII (VWF/FVIII) Concentrate in Adults and Children with von Willebrand Disease (VWD). (2007) (0)
Antihypertensive treatment changes and related clinical outcomes in older hospitalized patients (2022) (0)
[Behavior of malate dehydrogenase in normal human myelocytes and granulocytes and in myeloid leukemia cells]. (1965) (0)
A Two-Year Prospective Study on Bleeding Tendency In 105 Patients with Type 2 A and M Von Willebrand Disease (2010) (0)
Occult Cancer and Venous Thromboembolism (1998) (0)
CLINICAL AND MOLECULAR PREDICTORS OF THROMBOCYTOPENIA AND RISK OF BLEEDING IN PATIENTS WITH VON WILLEBRAND DISEASE TYPE 2B: A COHORT STUDY OF 67 PATIENTS Running title: Thrombocytopenia and bleeding risk in VWD 2B (2008) (0)
PHM2 THE COST OF CARE OF HEMOPHILIC PATIENTS WITHOUT INHIBITORS: THE COCHE STUDY (2005) (0)
[Comparison of 3 overall coagulation tests in hepatic cirrhosis. Evaluation of their diagnostic usefulness and correlation with the hemorrhagic tendency]. (1969) (0)
Are all licensed haemostatic agents for haemophilia therapy accessible to patients? (2022) (0)
Genome-wide association of early-onset myocardial infarction with single nucleotide polymorphisms and copy number variants Myocardial Infarction Genetics Consortium * (2009) (0)
The Molecular Genetic Analysis of Hemophilia A : A Directed Search Strategy for the Detection of Point Mutations in the Human Factor VI 11 Gene (2003) (0)
Predictors of Sustained Virological Response After Antiviral Therapy for Chronic Hepatitis C In Patients with Hemophilia: The Role of the Interleukin-28B (IL28B) Polymorphism (2011) (0)
Letter: Blood fractions for haemophilia. (1974) (0)
Questions and Answers – Workshop on Mobilizing Support for Haemophilia Care (Workshop II) (1981) (0)
Thrombolytic therapy in acute myocardial infarction (2005) (0)
Antibody to Hepatitis G Mrus after a Vapour-Heated Factor Vlll Goncentrate (1990) (0)
Combined estrogen-progestin oral contraceptives. (2004) (0)
Very Elderly Patients with Chronic Phase-Chronic Myeloid Leukemia on Imatinib: No Impact of Concomitant Drugs on Complete Cytogenetic Response (2015) (0)
JAK2 (V617F) Mutation and Cerebral Venous Thrombosis (2011) (0)
expression of the recombinant protein moderately severe factor V deficiency: molecular characterization by Arg2074Cys missense mutation in the C2 domain of factor V causing (2013) (0)
Abstract 13423: Pm10-Induced Nadph Oxidase Activation: A New Link Between Air Pollution and Oxidative Stress (2011) (0)
Conceptualizing a model for European health systems: the institutional framework. (2023) (0)
Abstract 2739: The Proprotein Convertase Subtilisin-kexin Type 9 (PCSK9) R46L Variant Is Associated With Reduced Serum Low-density Lipoprotein Cholesterol In The Italian Population (2007) (0)
Factor VIII Antibodies in Von Willebrand’s Disease (1977) (0)
How to win space in medical journals: Bits and tips. (2018) (0)
[Effect of raubasine and pipratecol on platelet aggregation and on the platelet release reaction]. (1980) (0)
Title Page / Table of Contents, Vol. 26, Supplement 4, 1996 (1996) (0)
Haematology and Haemophilia (1981) (0)
Antidiabetic Drug Prescription Pattern in Hospitalized Older Patients with Diabetes (2023) (0)
Factor VIII Deficiency or Hemophilia A: Clinical Bleeding and Management (2014) (0)
Rate of Inhibitor Development in Hemophilia A Patients Treated with Plasma Derived or Recombinant Factor VIII Concentrates. A Systematic Review of the Literature. (2009) (0)
Molecular analysis of severe von Willebrand disease in Italian patients. (1990) (0)
A thrombotic storm (2017) (0)
55 ISCHEMIC STROKE IN YOUNG ADULTS: GENETIC ANALYSIS OF 60 POLYMORPHISMS IN 17 GENES INVOLVED IN METHIONINE METABOLISM (2008) (0)
49Atrial Fibrillation and Dementia in the Oldest Old: An Analysis from the Population-Based Study 'Monzino-80 Plus' (2018) (0)
Increased prevalence of antibodies to protein s in inflammatory bowel disease (IBD) (1998) (0)
the COCIS Study Group Cost of care and quality of life in hemophilia complicated by inhibitors (2013) (0)
that has been in use for several years in our institution for patients with PVT. (2017) (0)
Air pollution, cardiovascular disease and urban greening: an ecological blueprint. (2023) (0)
Witnessing the 1980s (2020) (0)
Title Page / Table of Contents, Vol. 27, Suppl. 1, 1997 (1997) (0)
Contents, Vol. 10, Supplement 1, 1981 (1981) (0)
Brief report Missense or splicing mutation? The case of a ﬁbrinogen B (cid:1) -chain mutation causing severe hypoﬁbrinogenemia (2004) (0)
[New diagnostic methods for the pre-thrombotic state]. (1991) (0)
Prediction of Anti-FVIII Inhibitor Persistence By Anti-FVIII IgG Subclasses in Patients with Severe Hemophilia — A in the Sippet Cohort Study (2018) (0)
Performance of a clinical risk prediction model for inhibitor formation in severe haemophilia A (2021) (0)
Usefulness of Determination of Factor VIII Intron 7 Polymorphism by a Non-Radioactive Technique for Carrier Detection of Hemophilia A (1992) (0)
Undiagnosed coeliac patients may be at increased risk for thrombosis due to hyperhomocysteinemia (1998) (0)
Haemostasis parameters behaviour during haemodialysis without anticoagulants. (1983) (0)
Growing weapons to fight hemophilia (2023) (0)
Chapter 17. The Molecular Basis of Von Willebrand Disease (2007) (0)
Chapter 69 Bleeding and haemostasis disorders (2010) (0)
Partial inhibition of platelet aggregation by nebulized pentamidine in severe haemophiliacs (1997) (0)
[Left atrial rhythms]. (1969) (0)
CalciumDoes Not Interferewith Measurementof (1987) (0)
Characterization of a panel of monoclonal antibodies to von Willebrand Factor (vWF) and their use in a sensitive ELISA technique (1991) (0)
Exposure assessment 1 (2007) (0)
Interferon + ribavirin re-treatment in hemophilic patients relapsers or non-responders to interferon alone (2000) (0)
Biochemical Characterization of Recombinant Von Willebrand Factor (VWF) with a Type 2B Mutation (P1337L) Coexpressed with a Type 1 VWF Defect (C275R): A Complex Molecular Defect in a Patient Previously Diagnosed with Type 2A Von Willebrand Disease (VWD). (2004) (0)
Markers of activatedcoagulationand their usefulness in the clinicallaboratory (1996) (0)
ADAMTS-13 Binds Platelets in a Specific, Divalent Cation and Activation Dependent Manner. (2005) (0)
[Hypercoagulation and recurrence of cerebral infarct]. (1989) (0)
Offices of the Conference (1981) (0)
[Antiaggregant drugs: their pharmacology, mechanism of action and the interpretation of large trials]. (1990) (0)
P180 Increased Thrombin Generation in Inflammatory Bowel Diseases (2008) (0)
[ON BEHAVIOR OF ISOENZYMES OF LACTATE DEHYDROGENASE (LDH) IN THE ERYTHROCYTE OF FAVISM IN THE HEMOLYTIC PHASE]. (1964) (0)
Venous thromboembolism prophylaxis in elderly patients admitted to Italian internal medicine wards (2013) (0)
infections in multitransfused hemophilic patients Serum hepatitis B virus DNA detects cryptic hepatitis B virus (2011) (0)
HUMAN RECOMBINANT ERYTHROPOIETIN (rHuEpo) CORRECTS ANEMIA AND SHORTENS THE BLEEDING TIME (BT) IN UREMIC PATIENTS (1987) (0)
[Medical treatment of deep venous thrombosis]. (1985) (0)
[A new cause of thrombophilia]. (1996) (0)
Choices of factor VIII products in previously untreated patients with haemophilia A: A global survey (2018) (0)
Abstract (2003) (0)
[Electrophoretic fractionation of soluble proteins of normal and leukemic leukocytes]. (1964) (0)
Introduction (1994) (0)
Further comments on "High-titre inhibitors in previously untreated patients with severe haemophilia A receiving recombinant or plasma-derived factor VIII: a budget-impact analysis". (2019) (0)
Clinical and Biological Aspects of Essential Thrombocythemia (1985) (0)
[Platelet antiaggregants in post-myocardial infarct patients: why, which and in what doses?]. (1983) (0)
Another effect of desmopressin in ADAMTS-13 (2003) (0)
Transient decrease of thrombin generation during hirudin treatment in patients with acute coronary syndromes (1998) (0)
Impact of Dietary Fats on Cardiovascular Disease with a Specific Focus on Omega-3 Fatty Acids (2022) (0)
2 coagulation disorders factor VIII and IX deficiency: an index of different clinical severity of the Comparison of the rates of joint arthroplasty in patients with severe (2013) (0)
In Vitro Expression Studies And Immunofluorescence Microscopy Analysis Of Two Naturally Occurring Mutations On Factor X (FX) Gene (G94R And D95E) (2005) (0)
From the Editor‐in‐Chief (2003) (0)
Towards the impact factor (2005) (0)
BLEEDING TIME IN TREATED PATIENTS WITH SEVERE VON WILLEBRAND DISEASE IS NOT CORRECTED ONLY BY GIVING NORMAL MULTIMERIC PLASMA VON WILLEBRAND FACTOR (1987) (0)
PM Exposure Increases Coagulation Function. A Study Among Highly Exposed Steel Workers in Italy (2008) (0)
Factor V Leiden Is Associated with Premature Myocardial Infarction. (2008) (0)
Emicizumab in acquired hemophilia A: pros and cons of a new approach to the prevention and treatment of bleeding. (2023) (0)
Von Willebrand disease combined with coagulation defects in Iran. (2021) (0)
The following letter is in response to the preceding letter: .to the editor (1984) (0)
Prevalence of potentially inappropriate medications in a cohort of hospitalized elderly: Results from the REPOSI study (2013) (0)
SIPPET Slowly: This One's HOT! (2011) (0)
Thrombosis: The Start of a New Era for Antithrombotic Agents 21st International Congress, Milan, July 2010: Abstracts (2010) (0)
Blood platelets; progress and problems: Editorial (2001) (0)
JAK2 mutation [reply letter] (2007) (0)
[3 years of activity (1968-70) of a center for the care of hemophiliacs]. (1971) (0)
[Electrophoretic study of the soluble protein fraction of normal human granulocytes]. (1964) (0)
Pre-Conference Statements: Egli, H.: The Bonn Conference (1981) (0)
The αIIbP258S, a Newly Identified Mutation, and the αIIbG349D Substitutions Cause Glanzmann Thrombasthenia by Impairing αIIb-β3 Association in the Endoplasmic Reticulum. (2006) (0)
Biological Responses to Repeated Doses of Desmopressin (DDAVP) in Patients with Hemophilia and Von Wille Brand’s Disease (1993) (0)
Editorial (2006) (0)
CLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS The Incidence of Venous Thromboembolism in Asymptomatic Carriers of a Deficiency of Antithrombin, Protein C, or Protein S: A Prospective Cohort Study (2016) (0)
[Defibrination syndrome: treatment with an antifibrinolytic drug and anticoagulants]. (1967) (0)
Questions and Answers (Workshop III) (1981) (0)
Contents Vol. 32, 2002 (2002) (0)
Over-expression of beta antithrombin in familial antithrombin deficiency caused by an ASN135 to THR mutation (1997) (0)
[The Annals, which way does it go: the last two years (1996-1997)]. (1998) (0)
Molecular Mapping of the Chloride Binding Site in von Willebrand Factor (VWF): Energetics and Conformational Effects on the ADAMTS-13 Interaction with Wild Type and Type 2B R1306W VWF Forms. (2006) (0)
Prognostic value of coagulation parameters in liver transplantation (1990) (0)
9th BIC International Conference: Rome (Italy), 15-17 September 2017. (2017) (0)
Effectiveness of a Heated Prothrombin Complex Concentrate in Hemophiliacs with Inhibitors (1987) (0)
[6 years with Annali Italiani di Medicina Interna]. (2000) (0)
Protein C,An Inhibitor of Blood Coagulation, in Liver Disease and other Clinical Conditions (1984) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Pier Mannuccio Mannucci?

Pier Mannuccio Mannucci is affiliated with the following schools:

Pier Mannuccio Mannucci's Academic­Influence.com Rankings

Pier Mannuccio Mannucci's Degrees

Similar Degrees You Can Earn

Why Is Pier Mannuccio Mannucci Influential?

Pier Mannuccio Mannucci's Published Works

Published Works

What Schools Are Affiliated With Pier Mannuccio Mannucci?

Pier Mannuccio Mannucci's AcademicInfluence.com Rankings